For the first time, researchers at the Center for Cell-Based Therapy (CTC) in Ribeiro Preto, Brazil, have identified a non-hereditary mutation in blood cells from a patient with GATA2 deficiency.

GATA2 deficiency is a rare autosomal disease caused by inherited mutations in the gene that encodes GATA-binding protein 2 (GATA2), which regulates the expression of genes that play a role in developmental processes and cell renewal.

An article on the study is publishedin the journalBlood.

The non-hereditary mutation may have acted as a natural gene therapy which prevented the disease from damaging the process of blood cell renewal. This meant that the patient did not develop such typical clinical manifestations as bone marrow failure, hearing loss, and lymphedema.

The researchers say that the findings pave the way for the use of gene therapy and changes to the process of checking family medical history and medical records for families with the hereditary disorder.

Luiz Fernando Bazzo Catto, first author of the article, said: When a germline [inherited] mutation in GATA2 is detected, the patients family has to be investigated because there may be silent cases.

The discovery was made when two sons were receiving medical treatment at the blood centre of the hospital run by FMRP-USP, both of which, in post-mortem DNA sequencing, showed germline mutations and GATA2 deficiency diagnosis. The researchers used next generation sequencing to estimate the proportion of normal blood cells in the fathers bone marrow, preventing clinical manifestations of GATA2 deficiency, and of cells similar to his childrens showing that 93% of his leukocytes had the mutation that protects from the clinical manifestations of GATA2 deficiency.

Following the sequencing of the fathers T-lymphocytes, the researchers found that the mutation occurred early in their lives and in the development of hematopoietic stem cells, which have the potential to form blood.

They also measured the activity of the blood cells, to see if they could maintain the activity of inducing normal cell production for a long time, by measuring the telomeres of his peripheral blood leukocytes. Telomeres are repetitive sequences of non-coding DNA at the tip of chromosomes that protect them from damage. Each time cells divide, their telomeres become shorter. They eventually become so short that division is no longer possible, and the cells die or become senescent.

The telomeres analysed by the researchers were long, indicating that the cells can remain active for a long time.

The researchers hypothesised that the existence of the somatic mutation in the fathers blood cells, and its restoration of the blood cell renewal process, may have contributed to the non-manifestation of extra-haematological symptoms of GATA2 deficiency such as deafness, lymphedema, and thrombosis.

Professor Rodrigo Calado, a corresponding author of the article, said: A sort of natural gene therapy occurred in this patient. Its as if he embodied an experiment and a medium-term prospect of analogous gene therapy treatment in patients with GATA2 deficiency.

The findings help us understand better how stem cells can recover by repairing an initial genetic defect.

Recommended Related Articles

View original post here:
Non-hereditary mutation acts as natural gene therapy for GATA2 deficiency - Health Europa

Recommendation and review posted by Bethany Smith

A succinct analysis of market size, regional growth and revenue projections for the coming years is presented in GlobalStem Cells Marketreport. The study further sheds light on major issues and the new growth strategies implemented by manufacturers that are part ofcompetitive landscape of the studied market.Thereport offers key trends, investment opportunities and drivers in Global Stem Cells Marketwith the latest market intelligence by adopting primary and secondary research methods. It also includes strategies adopted in the context of acquisitions and mergers, and business footprint extensions.

In order to provide more exactmarket forecast, the report comprises a complete research study and analysis ofCOVID-19 impact on the Global Stem Cells market. It also considers the strategies that can be adopted to deal with the situation.

Get sample [emailprotected] https://www.kdmarketinsights.com/sample/3333

Competitive Landscape and Stem Cells Market Share Analysis:

The competitive landscape of the Stem Cells market provides data about the players operating in the studied market. The report includes a detailed analysis and statistics onprice, revenue and market share of the playersfor the period 2020-2025. The major players covered are as follows:

Thermo Fisher Scientific Inc.

Cellular Engineering Technologies Inc

Qiagen N.V

Sigma Aldrich Corporation

Becton, Dickinson and Company

Miltenyi Biotec

International Stem Cell Corporation

Stem Cell Technologies Inc.

Pluristem Therapeutics Inc

Medtronic, Inc

Zimmer Holdings, Inc.

Bio Time Inc

Zimmer Holdings, Inc

Orthofix, Inc.

Osiris Therapeutics Inc

Others Prominent Players

Key segments covered:

By Product

Adult Stem Cells

Neural Stem Cells

Hematopoietic Stem Cells

Mesenchymal Stem Cells

Umbilical Cord Stem Cells

Epithelial Stem cells and Skin Stem Cells

Others

Human Embryonic Stem Cells

Induced Pluripotent Stem Cells

Others

By Application

Regenerative Medicine

Neurology Regenerative Medicine

Oncology Regenerative Medicine

Myocardial Infraction Regenerative Medicine

Diabetes Regenerative Medicine

Hematology & Immunology Regenerative Medicine

Orthopedics Regenerative Medicine

Other Regenerative Medicine

Drug Discovery and Development

Other Applications

By Technology

Cell Acquisition

Bone Marrow Harvest

Umbilical Blood Cord

Apheresis

Others

Cell Production

Therapeutic Cloning

In-vitro Fertilization

Cell Culture

Isolation

Cryopreservation

Expansion and Sub-Culture

By End-User

Biopharmaceutical

Biotechnology Industry

Research Institutes

By Treatment Type

Allogeneic Stem Cell Therapy

Auto logic Stem Cell Therapy

Syngeneic Stem Cell Therapy

By Banking Type

Public

Private

By Region:

North America (U.S. & Canada)

Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (GCC, North Africa, South Africa, and Rest of Middle East & Africa)

Get Complete Research Report with [emailprotected]https://www.kdmarketinsights.com/product/3333/stem-cells-market

Some Important Highlights from the Report include:

Market CAGR during the 2020-2025 forecast period.

Comprehensive analysis on factors that will speed up the growth of Stem Cells marketover the next five years.

Precise estimates about the market size of global Stem Cells market and itscontribution to the parent market.

Precise forecasts for future developments in the Stem Cells industry and shifts in consumer behavior.

The growth of the Stem Cells Market across the Americas, APAC, Europe and MEA.

A detailed analysis of the industry competition and quantitative data on various vendors.

Comprehensive information on variables that will impede the growth of Stem Cells companies.

The Following are the Key Features of Global Stem Cells Market Report:

Market Overview, Industry Development, Market Maturity, PESTLE Analysis, Value Chain Analysis

Growth Drivers and Barriers, Market Trends & Market Opportunities

Porters Five Forces Analysis & Trade Analysis

Market Forecast Analysis for 2020-2025

Market Segments by Geographies and Countries

Market Segment Trend and Forecast

Market Analysis and Recommendations

Price Analysis

Key Market Driving Factors

Stem Cells Market Company Analysis: Company Market Share & Market Positioning, Company Profiling, Recent Industry Developments etc.

Why Choose KD Market Insights?

Provides accurate data and best-in class solutions to our clients.

Offers optimal market predictions and analysis of the business.

Ensures that clients gain unmatched competitive advantage, builds more competent organizations, and ensures enduring outcomes.

Get Discount [emailprotected]https://www.kdmarketinsights.com/discount/3333

About Us:

Read the rest here:
Stem Cells Market Detailed Analysis by On-going Trends, Prominent Size, Share, Sales and Forecast to 2025 - PRnews Leader

Recommendation and review posted by Bethany Smith

Post Views: 2,218

BioRestorative Therapies Inc (OTCMKTS: BRTXQ) (BRTX) is soaring up the charts after it was revealed at 12.04 pm Wednesday afternoon the Company was emerging from bankruptcy. BRTXQ came to the attention of many penny stock speculators after the Company partnered on a new bankruptcy reorganization plan with one of its creditors Auctus Capital in which it would emerge from bankruptcy with the commons intact, ready to begin phase 2 trials and get BioRestorative back on a national stock exchange.

BioRestorative Therapies has received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs. BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. It is the Companys intend that the product be used for the non-surgical treatment of painful lumbosacral disc disorders.

BioRestorative Therapies Inc (OTCMKTS: BRTX) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: Disc/Spine Program (brtxDISC): Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders.

The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The Company has received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

To Find out the inside Scoop on BioRestorative Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Metabolic Program (ThermoStem): the Company is developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

BioRestorative owns a valuable intelectual property portfolio including unique international Stem Cell patents as well as 8 patents issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program).

For More on BRTX Subscribe Right Now!

BioRestorative Therapies is making a powerful move up the charts after it was it was revealed at 12.04 pm Wednesday afternoon the Company was emerging from bankruptcy. This comes after the Company successfully entered into a reorganization plan with one of its creditors Auctus Capital after its March Bankruptcy filing in which the Company would emerge from bankruptcy with the commons intact, ready to begin their phase 2 trials and get BioRestorative back on a national stock exchange. BioRestorative Therapies has received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs. BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. It is the Companys intend that the product be used for the non-surgical treatment of painful lumbosacral disc disorders. We will be updating on BioRestorative when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with BioRestorative.

Disclosure: we hold no position in BRTX either long or short and we have not been compensated for this article.

Share.

Follow this link:
BRTX-100; the Story of BioRestorative Therapies Inc (OTCMKTS: BRTX) - MicroCap Daily

Recommendation and review posted by Bethany Smith

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ:MESO) and certain of its officers. The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-09111, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Mesoblast securities between April 16, 2019 and October 1, 2020, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").

If you are a shareholder who purchased Mesoblast securities during the class period, you have until December 7, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at http://www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial to treat children with steroid refractory ("SR") acute graft versus host disease ("aGVHD").

In early 2020, Mesoblast completed its rolling submission of its Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA") to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD.

Story continues

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD because of design differences between the four studies; (ii) as a result, the FDA was reasonably likely to require further clinical studies; (iii) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (iv) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 11, 2020, the FDA released briefing materials for its Oncologic Drugs Advisory Committee ("ODAC") meeting to be held on August 13, 2020. Therein, the FDA stated that Mesoblast provided post hoc analyses of other studies "to further establish the appropriateness of 45% as the null Day-28 ORR" for its primary endpoint. The briefing materials stated that, because of design differences between these historical studies and Mesoblast's submitted study, "it is unclear that these study results are relevant to the proposed indication."

On this news, the Company's American Depositary Share ("ADS") price fell $6.09 per share, or approximately 35%, to close at $11.33 per share on August 11, 2020, on unusually heavy trading volume.

On October 1, 2020, Mesoblast disclosed that it had received a Complete Response Letter ("CRL") from the FDA regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that the Company "conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD." The CRL also "identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product's biologic activity."

On this news, the Company's ADS price fell $6.56 per share, or over 35%, to close at $12.03 per share on October 2, 2020, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See http://www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

View source version on accesswire.com: https://www.accesswire.com/617512/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Reminds-Shareholders-with-Losses-on-their-Investment-in-Mesoblast-Limited-of-Class-Action-Law-Suit-and-Upcoming-Deadline-MESO

Follow this link:
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Law Suit and Upcoming...

Recommendation and review posted by Bethany Smith

TEL AVIV, Israel, Nov. 18, 2020 /PRNewswire/ --BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections.

The open-label, single-arm, Phase 1b study will be conducted at the Wolfson Medical Center in Holon, Israel, with Dr. Yasmin Maor, Head of the Infectious Disease Unit, as lead investigator.

"Severe COVID-19 cases, where patients are hospitalized with ARDS and require ventilation, have generated renewed interest in the underlying pathology of acute respiratory stress disorder," noted Dr. Maor. "Substantial data is emerging regarding the involvement of neutrophils, neutrophil extracellular traps (NETs), monocytes and macrophages in the development of ARDS secondary to COVID-19 and other viral infections; as well as the key involvement of CXCR4 as a mediator of those cells in the inflamed pulmonary tissue. Based on the scientific data indicating the importance of blocking the CXCR4/CXCL12 axis during ARDS, Motixafortide could be of potential benefit for such patients. COVID-19 case counts are again surging in many parts of the world and addressing ARDS has become a top global health priority."

The primary endpoint of the study is to assess the safety of Motixafortide in patients with ARDS secondary to COVID-19 and other respiratory viral infections. Respiratory parameters and inflammatory biomarkers will be assessed as exploratory endpoints. Up to 25 patients will be enrolled, with a preliminary analysis planned after ten patients have completed the initial treatment period. Based on the preliminary evaluation, a decision to continue or not will be conducted by Dr. Maor, together with the Company.

"We believe there is strong scientific rationale for exploring Motixafortide in ARDS, and we are grateful to Dr. Maor for initiating this study," stated Philip Serlin, Chief Executive Officer of BioLineRx. "We have compiled a significant body of data demonstrating Motixafortide's utility as a best-in-class CXCR4 inhibitor and we are eager to evaluate its effectiveness in blunting the cytokine storm that is associated with poor COVID-19 infection outcomes. We look forward to results from the preliminary analysis in the first half of next year.

"In parallel, we remain on track to announce full data from our Phase 2a COMBAT/KEYNOTE-202 study in pancreatic cancer, as well as interim results from our Phase 2b BLAST study in AML, by the end of this year," Mr. Serlin concluded.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, and for which positive data in respect of the study's primary endpoint was recently announced from an interim analysis, resulting in early cessation of recruitment. Motixafortide is also being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy under a collaboration agreement with MSD, as well as a Phase 2b study in consolidation AML.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; risks related to the coronavirus outbreak; and statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:Tim McCarthyLifeSci Advisors, LLC+1-212-915-2564[emailprotected]

or

Moran MeirLifeSci Advisors, LLC+972-54-476-4945[emailprotected]

SOURCE BioLineRx Ltd.

Follow this link:
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other...

Recommendation and review posted by Bethany Smith

The idea of repurposingexisting medicines as a fast approach to containing COVID-19 is still popular, even as vaccines and antibodies designed to combat the disease are starting to gain steam. Scientists at the Cleveland Clinic are among those examining existing compounds as possible treatments for the coronavirus, and now they're suggesting that the popular over-the-counter sleep aid melatonin may be a possible option in treating the disease.

The researchers used an artificial intelligence tool to analyze data from 26,779 individuals in the Cleveland Clinics COVID-19 registry, of whom 8,274 tested positive for SARS-CoV-2, the novel coronavirus that causes COVID-19.

They found that people who were taking melatonin were 28% less likely to test positive for SARS-CoV-2, after adjusting for factors such as age, sex and underlying diseases, according to results published in the journal PLOS Biology.

The melatonin effect was more pronounced in African Americans, with a reduction of 52%. In White Americans, the number was 23%.

Melatonin is a hormone released by the body that regulates the sleep-wake cycle. As a dietary supplement, its commonly used to help manage insomnia andjet lag.

Besides melatonin, the Cleveland Clinic team also found that the beta-blocker carvedilol, sold under the brand Coreg for high blood pressure and other heart diseases, was associated with a 26% reduction in a persons chance of testing positive for SARS-CoV-2.

RELATED:Melatonin? Stem cells? Researchers step up with unconventional approaches to COVID-19

Some members of the same Cleveland Clinic team previously pinpointed melatonin among a group of drugs they suggested might work for COVID. They showed that melatonin and mercaptopurine might work as a good combo for COVID. Those findings came from a pharmacology-based platform that used a technique called network proximity analysis. It was based on the idea that some proteins involved in other diseases might hold proximity to a virus interaction with the host.

The researchersapplied the same method in the current study to shed a light on clinical manifestations and pathologies common between COVID-19 and 64 other diseases. Closer proximity would mean a higher likelihood of pathological associations between the diseases.

They found that proteins involved in respiratory distress syndrome and sepsis were highly connected with SARS-CoV-2. That wasnt a surprise given that the two disorders can also cause death in patients with severe COVID-19.

This signals to us that a drug already approved to treat these respiratory conditions may have some utility in also treating COVID-19 by acting on those shared biological targets, Feixiong Cheng, Ph.D., the studys senior author, said in a statement.

Overall, they identified close network proximity to SARS-CoV-2 proteins from inflammatory bowel disease, attention deficit hyperactivity disorder, as well as pulmonary diseases such as COPD. Using a computational model, they identified 34 drugs that were significantly proximal to two or more SARS-CoV-2 host protein sets.

RELATED:COVID-19: Bio researchers race to repurpose everything from antiviral to anticancer discoveries

A team at Columbia University has also linked melatonin with increased likelihood of clinical improvement among critically ill COVID-19 patients on intubation or mechanical ventilation.

The sleep-promoting supplement was also reportedly used by President Donald Trump during his COVID-19 infection, though its not clear if he was taking it specifically to treat the disease or as part of his daily nutrition routine.

Despite melatonin emerging as a top pick from the Cleveland Clinic registry, Cheng cautioned that larger, randomized control trials would be needed before the supplement could be widely adopted in the treatment of COVID-19.

Cheng added that AI-based approaches to analyzing COVID-19 patient registries should be embraced in the effort to find effective treatments for the disease.Recent studies suggest that COVID-19 is a systematic disease impacting multiple cell types, tissues and organs, so knowledge of the complex interplays between the virus and other diseases is key to understanding COVID-19-related complications and identifying repurposable drugs, Cheng said. Our study provides a powerful, integrative network medicine strategy to predict disease manifestations associated with COVID-19 and facilitate the search for an effective treatment.

See more here:
Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech

Recommendation and review posted by Bethany Smith

SEATTLE A federal judge in Seattle has awarded $10 million to the family of a severely disabled child who was born after a community clinic nurse inadvertently gave the mother a flu shot instead of a birth-control injection.

The Seattle Times reported that US District Judge Robert Lasnik last week awarded the child $7.5 million for her medical, educational and other expenses, on top of $2.5 million in damages for her parents.

After a trial earlier this year, Lasnik found that the mother, Yeseni Pacheco, did not want to become pregnant and would not have become pregnant in 2011 if the nurse at the Neighborcare Health clinic had given her the correct shot.

The federal government is responsible for the damages because the clinic, which serves low-income and uninsured patients, is federally funded.

The familys lawyers, Mike Maxwell and Steve Alvarez, described the case in court documents as a wrongful pregnancy and wrongful life case. They said the case was a hard-fought battle and sharply criticized the government for refusing to accept responsibility at the outset.

Luis and Yesenia Pacheco are pleased that theyre closer to receiving the funds needed for their daughters extraordinary medical care and training, they wrote in a statement. It was a long hard road for the family.

Emily Langlie, a spokeswoman for the US Attorneys Office in Seattle, which defended the lawsuit, said some of the delays were necessary to ensure medical experts could accurately measure the extent of the childs disabilities.

Pacheco, an El Salvadoran refugee who moved to the US when she was 16, had gone to the clinic for a quarterly injection of Depo-Provera, a hormone used for birth control.

A nurse at the clinic who had been administering walk-in flu shots all day apparently did not check Pachecos chart and gave Pacheco the flu vaccine instead, the court found.

Pacheco didnt discover the mistake until she called to make her next appointment, more than two months later. By then, she was pregnant.

The child is now 8 years old and in third grade at an Everett-area school, north of Seattle.

According to court documents, she suffers from a birth defect known as bilateral perisylvian polymicrogyria (PMG), which has resulted in cognitive delays, slowed speech and language skills, epilepsy, vision problems and other complications.

She has an IQ of 70, according to the familys attorneys. Maxwell said that she will live a normal life span, and will require some level of care and assistance for her entire life.

Justice Department lawyers are asking that some of the award be placed in a reversionary trust that would return to the government if the girl does not need it.

See the rest here:
Judge awards $10M to family in 'wrongful life' case - West Haven Observer

Recommendation and review posted by Bethany Smith

While people are glad to have access to technology like Zoom and Facetime to stay connected with friends and family, this does not fully meet the need for social interaction that human beings need to thrive, said Dr. Emily Sander, psychologist at Mayo Clinic Health System in Red Wing. The reality of human connection is that aspects of communication that build trust and connection, such as touch and eye contact, cannot be accomplished via video technology.

Online meetings she has observed during the pandemic involve more uncomfortable silence as well as less social chatter, less laughing than pre-pandemic in-person meetings. She said this might be caused by failing to activate our mirror neurons, which are brain cells that allow us to reflect the facial expressions, body language, and emotions of others.

Emily Sander, psychologist at Mayo Clinic Health System in Red Wing. Submitted photo

When humans are together, these mirror neurons activate automatically, giving us a wealth of data that fosters communication, connection, and learning, Sander said. When we are not able to be physically present with others, we are left without much of this data, and the quality of the interaction is diminished.

Jessica Wiskow, school counselor at Ellsworth High School, said extended online meetings and classes have caused Zoom fatigue in some of the teachers.

So much of our communication comes from nonverbal cues, and when in groups where people are only focusing on the main speaker many nonverbal cues are missed, Wiskow said. I think its hard to feel engaged and supported when half of the message is lost in translation.

She said the strength of human relationships is critical in education. Teachers and staff at Ellsworth High School have been working

Jessica Wiskow, counselor at Ellsworth High School in Ellsworth. Submitted photo

I feel this paid off last spring when we were shut down, she said. We were able to cash in some of the relationship equity we built with the students to engage them during a very scary time.

Another concern about screen time is the drug-like effect it can have on the brain, because screen-based activities trigger the release of dopamine, which Sander said is often called the happy hormone.

These activities impact the reward system in the brain in a way that is similar to addictive substances or addictive behaviors, like gambling, Sander said. This was an issue in households across the world long before COVID-19, but the limitations of the pandemic have made finding alternatives to screentime far more difficult for many individuals and families.

For students, distance learning has created problems with appropriate study spaces, anxiety, parental support, and learning styles.

If there is one thing that this pandemic has confirmed for me is that every individual child and adolescent learns differently, Sander said. The primary motivator that makes many students excited to go to school each day is simply not the same in a distance-learning format, and that is getting to spend time with friends.

Sitting for hours in front of a screen is not healthy for anyone, Sander said, and she encourages families to set up screen free times and model healthy boundaries in using devices. Breaking sessions of screen time up with other activities, especially those that involve some movement like sports, yoga, games or family walks can provide relief from added screen time.

Movement supplies oxygen to the brain, promotes the creation of new brain cells, and helps those brain cells make connections, Sander explained. Movement also increases energy, reduces stress, and soothes the mind and bodily tension.

With many families involved in remote work as well as distance learning, it may be harder to keep to some standard routines like getting enough sleep.

I firmly believe that every household should have a tech curfew where screens are put away at least 30 minutes prior to bedtime each night, Sander said.

Sander said some adults who feel limited using technology might experience more distress when they attempt to communicate and struggle with the technology.

While there are many challenges related to the increase in screen time in all of our lives, every challenge we face in life is an opportunity for growth, Sander said. As we learn to navigate this very new world of heavy screen use in schools, the workplace, and home, I encourage individuals and families to examine their individual needs and to learn to advocate for those needs whenever possible.

As COVID cases continue to increase, no one knows how long our current situation will last, how long the additional screen time will be our lifestyle. Because mobile devices and tablets are relatively new, Sander said our understanding of the impact of screen time on the human brain is also new and is increasing.

While some of the effects may be negative, she recognizes one thing that gives her hope.

Humans are capable of resilience, she said. We can dig in and be resilient for a while, then we see a bit of a crash. People have to regroup and let themselves experience the grief that comes along with all of the changes that we are seeing, then pick ourselves up and continue. My suspicion is that is what we are going to see over time.

See the rest here:
Screen time increases with pandemic adjustments - RiverTowns

Recommendation and review posted by Bethany Smith

Since the FDA approved the abortion pill mifepristone in 2000, self-managed at-home abortions in the US have become increasingly common.

According to the Guttmacher Institute, 39% of all abortions in 2017 were carried out with the abortion pill, also known as medication abortion, compared to 29% in 2014.

With many states still lacking widespread abortion clinic access and the imminent challenging of Roe v. Wade which says pregnant women have the right to abortions without excessive government intervention self-managed abortions with the pills mifepristone and misoprostol are likely to become especially sought-after, Carole Joffe, sociologist and co-author of "Obstacle Course: The Everyday Struggle to Get an Abortion in America,"told Insider.

Here's everything you need to know about medication abortion.

Two pills, mifepristone and misoprostol, are used together to complete a self-managed abortion, Yale University gynecologist Dr. Mary Jane Minkin told Insider.

After a healthcare provider explains other abortion options and completes lab tests to ensure you're a good candidate for medication abortion, you'll be given mifepristone and misoprostol, directions on how to use the pills, and a number to call if you need assistance during or after the abortion.

At home, you'll first take the mifepristone, which blocks the production progesterone, a hormone needed to sustain a pregnancy. Right after or up to two days later, depending on your doctor's instructions, you'll take misoprostol, a drug that causes the uterus to contract and pushes the embryo or fetus out of your body.

"You will be experiencing, in a sense, a miscarriage," Minkin said.

Misoprostol normally causes cramping and bleeding one to four hours after a patient takes it, according to Planned Parenthood.

Sometimes a self-managed abortion is only done with mifepristone, but research has shown that using both drugs in tandem leads to better outcomes because it prevents the potential need for surgery to remove the fetus.

Afterwards, you'll have a follow-up appointment with a doctor to make sure the abortion is complete.

A person can do a self-managed abortion up to 11 weeks after the first day of their menstrual cycle, Minkin said.

After that, you'd have to explore other options. People with IUDs, bleeding disorders, a suspected ectopic pregnancy, or who are allergic to the pills can't get medication abortions, according to the Mayo Clinic.

The effectiveness of the abortion pill changes depending on close you get to the 11-week cutoff.

For example, the pill is effective between 94% and 98% effective for people who are less than eight weeks pregnant. But for people who are nine to 10 weeks pregnant, the pill is effective 91% to 93% of the time, the Planned Parenthood website says.

Sometimes doctors will prescribe an extra dose of medicine for patients who are closer to the 11-week threshold, which can increase effectiveness, according to Planned Parenthood.

To get the drugs you need for a self-medicated abortion, you'll need to see a gynecologist who's trained and licensed to give you the pills. Most gynecologists have this ability, Minkin said, and you can call and ask ahead of time if you're unsure.

If you can't access a gynecologist in your area, you can order the pill online.

Carafem, a reproductive healthcare provider in Maryland, Georgia, Tennessee, Washington DC, and Illinois, offers both in-person and telemedicine medicated abortion services.

People who want the pill in these states but don't live in driving distance of a brick-and-mortar provider can set up an encrypted video meeting with a physician and then they'll be sent the pills in the mail, according to chief operating officer Melissa Grant.

Grant said Carafem in-person clinics are located in close proximity to states that don't have easy abortion access. Over the summer, Carafem found 30% of their clients drove more than 100 miles to get to their clinics in Washington DC, Nashville, Chicago, and Atlanta, Grant said.

Minkin said medicated abortion is typically less expensive than in-clinic, but cost varies based on your location and insurance coverage.

According to Planned Parenthood, the pill can cost up to $1,000 without insurance.

If you have Medicaid and need an abortion due to rape, incest, or life endangerment due to carrying a pregnancy, all states cover the cost of the pill, according to the Kaiser Family Foundation.

Due to a piece of legislation called The Hyde Amendment, 16 other states use their own funds to cover abortions, including the pill, for reasons outside of the three previously mentioned if you have Medicaid.

Though rare, there are complications that can occur after a self-managed abortion, including excessive bleeding, blood clots, and infection.

If you have any of these symptoms, contact your healthcare provider right away and go to the hospital.

Read more here:
Everything you need to know about the abortion pill, according to a gynecologist - Insider - INSIDER

Recommendation and review posted by Bethany Smith

Karen Russell, MD, Tallahassee Memorial HealthCare Published 12:36 p.m. ET Nov. 16, 2020

Karen Russell, the medical director for cancer research, talks about the importance of research and clinical trials.

Dr. Karen Russell, a cancer and hematology specialist at Tallahassee Memorial HealthCare, speaks with a breast cancer patient at the chemotherapy infusion and exam area of the Cancer Center of the hospital.(Photo: Joe Rondone/Democrat)

While this year has brought a new normal for us all, we found cancer was somewhat hidden in the shadows as the world focused on the COVID-19 pandemic. Nevertheless, cancer unfortunately continued to be disruptive and deadly, especially breast cancer.

Today, breast cancer remains the No. 1cancer in incidence for women and men combined in the United States (not including non-melanoma skin cancers). Through improved access to prevention and better treatment options, it is no longer the highest in mortality as death rates have dropped 40 percent for women between 1989 and 2017.

Yet this year alone an estimated 42,000+ deaths are predicted in the United States (American Cancer Society), which is still too many. With these daunting statistics in mind, we get to work to find a cure.

Every advancement in breast cancer care and prevention has been the result of a clinical trial and the patients who have participated in these trials. Paving the way for progress, clinical trials are how we improve healthcare and ultimately, save lives.

At Tallahassee Memorial HealthCare, we are proud to offer an international network of clinical trials for cancer patients in the Big Bend. Clinical trials are an important piece of the complete care offered at TMH, as they provide the opportunity for patients to receive new and cutting-edge treatments.

Currently, we have six clinical trials active specifically for breast cancer patients. These trials are a mix of large, often government or public sector funded, cooperative group trials among many cancer centers around the world, alternately, those directly run by pharmaceutical companies testing new drugs or new timing/indication for drugs that have worked well.

Four current studies are in the area of aggressive estrogen positive or triple negative breast cancer, using added chemotherapy or immunotherapy before or after surgery in hopes for prevention of recurrence and increased cure.

BWEL is an ongoing cooperative trial led by the Dana Farber Cancer Institute. This study is an intervention of weight loss and fitness counseling after treatment of early breast cancer, where there has been suggestive data that healthy weight and exercise can decrease cancer recurrence. We continue to see robust enrollment to this trial and are encouraged by the patient experience.

We are also part of an anonymous cancer registry trial that compiles data on side effects and quality of life for our patients to improve holistic care. This clinical trial is available to all cancer types.

Finally, we continue to follow patients in an ongoing phase three trial already reporting positive results, using the new drug abemaciclib with hormone blocking therapy after standard treatment. Patients with estrogen expressing breast cancers receiving the new drug have lower recurrence rates (less cancer coming back) in the time studied to date.

In the next few months, we are excited to expand this portfolio with additional trials of novel drugs that continue to offer life-changing results for our patients. Specifically, we will soon be contributing to the COVID-19 Cancer Consortium (CCC-19) led by Vanderbilt University, to further understand how cancer patients have experienced COVID at various stages of their therapy.

Unfortunately, only about three percent of U.S. adult patients with cancer enroll in clinical trials, largely because there is a lack of access for patients to clinical research in many communities. At the very heart of improving cancer care, there must be a local cancer clinic providing accessibility to the people who need it most, and TMH is proud to be the leader in comprehensive cancer care providing access to our region.

We thank you for your continued support for the cancer services and patients at Tallahassee Memorial Cancer Center. For more information on clinical trials, visit TMH.ORG/Cancer.

Dr. Karen Russell(Photo: Tallahassee Memorial HealthCare)

Karen Russell, MD, medical oncologist at Tallahassee Memorial HealthCare

Never miss a story: Subscribe to the Tallahassee Democrat using the link at the top of the page.

Read or Share this story: https://www.tallahassee.com/story/life/causes/2020/11/16/cure-cancer-research-clinical-trials-pave-way-tmh/6284190002/

Read the original:
Cure for cancer is research: Clinical trials pave the way at TMH - Tallahassee Democrat

Recommendation and review posted by Bethany Smith

DEIR AL-BALAH, Gaza Strip, Palestine I always encourage the women I know to do a self-examination and regular screenings, Intisar, 55, told UNFPA. She is a breast cancer survivor from Deir al-Balah in the Gaza Strip, and her outspokenness about the topic is a rarity in her community.

The incidence of breast cancer has been increasing in Palestine in recent years partly due to growing awareness and detection, but also because of lifestyle and dietary habits related to poverty. It is the most prevalent cancer among Palestinian women, accounting for 32 per cent of cancer diagnoses in the West Bank and 18 per cent of those in the Gaza Strip.

Breast cancer is most treatable when detected early. Unfortunately, more than 60 per cent of breast cancer cases in Palestine are found at a late stage, reducing the chance of survival.

Women with breast cancer also face serious stigma.

In Palestine, it is widely understood that vulnerability to breast cancer can be hereditary. As a result, some women avoid getting screened because they fear a breast cancer diagnosis could affect their daughters marriage prospects. Women with breast cancer have also faced gender-based violence and abandonment. A recent UNFPA study showed that breast cancer stigma is a major cause of delayed detection and treatment.

Intisar was fortunate to have the support of her family when she received her breast cancer diagnosis in 2016. But the social stigma left her feeling depressed and isolated.

UNFPA works with the Ministry of Health to improve detection and treatment efforts, and coordinates a breast cancer working group.

Working with Augusta Victoria Hospital and the Palestinian Medical Relief Society, and with funding from the Government of Japan, UNFPA has deployed a mobile breast cancer screening clinic to marginalized communities in the West Bank.

UNFPA also works closely with the Culture and Free Thought Association (CFTA) and the Campaign for the Children of Palestine to support breast cancer patients in Gaza. After Intisar received chemotherapy, she started to visit the CFTA for services.

There, she received a wig, dignity kits with hygiene products, hormone therapy, vitamins, medication and financial assistance. The association also helped her receive a mastectomy operation and prostheses. CFTA also provided psychosocial support, recreational activities and group outings.

I met women who became my real friends, Intisar recalled.

These services, as well as community awareness sessions, are supported by UNFPA with funding from the Government of Japan. Awareness is essential, experts say.

The aim is to increase awareness on the importance of early diagnosis for breast cancer for both women and men, said Firyal Thabet, director of the Women Health Centre at CFTA.

We do this by online campaigns, radio coverage, and by involving mosques, hair salons and taxi companies. Now we see more and more women and men coming to our centre for screening.

Swift access to treatment services is also crucial. A recent evaluation of UNFPAs projects on breast cancer found that, among the projects clients, the average time from diagnosis to initiation of treatment fell from 6 months to 7 days between 2016 and 2018.

Still, some treatment options remain out of reach.

Intisar needed to receive radiotherapy, but no such services were available in Gaza. CFTA helped her obtain a permit from the Israeli authorities to receive treatment at Augusta Victoria Hospital in East Jerusalem, but her permit application was rejected five times before she was finally granted permission.

In 2018, almost 40 per cent of Israeli permit applications for Palestinian patients to exit the Gaza Strip to receive treatment in the West Bank or Jerusalem were rejected or delayed. About a quarter of these applications were for cancer care.

Today, Intisar is a leading advocate for early detection and a peer supporter at CFTA. She also counsels women and girls about the topic in her community. Breast cancer is a start of a new life and not the end of your life, she tells them. Do not give up.

She is also refusing to give up.

A year ago, doctors found a small cancerous tumour on her lung. She is again undergoing chemotherapy.

I am hopeful that I will recover again, she said, with the help of God and those around me.

Continue reading here:
For one breast cancer survivor in Gaza Strip, a journey of hardship and hope - occupied Palestinian territory - ReliefWeb

Recommendation and review posted by Bethany Smith

Summary

The New York Power Authority today announced the first milestone of its 15-year modernization and digitization program to significantly extend the operating life of its Niagara Power Project, the largest source of clean electricity in New York State and one of the country's largest hydroelectric projects.

The New York Power Authority today announced the first milestone of its15-year modernization and digitization program to significantly extend the operating life of its Niagara Power Project, the largest source of clean electricity in New York State and one of the country's largest hydroelectric projects. As part of the Robert Moses Niagara Power Plants life extension and modernization program, called "Next Generation Niagara," 13 turbine units in the project's main generating facility will be upgraded. An outage to allow for the overhaul of the first unit began recently and digitization and modernization work commenced earlier this month.

The digitization of the first hydroelectric generator at the Robert Moses Power Plant is significant because it will set the course for work on the remaining twelve units, said Gil C. Quiniones, NYPA president and CEO. We have been planning this work for many months, but as the old saying goes, this is where the rubber meets the road.

Next Generation Niagara was launched in July 2019. Next Gen improvements include replacing aging equipment with the latest machinery reflecting advanced digital technologies for optimizing the hydroelectric project's performance. The initiative encompasses four major phases. 1) A comprehensive inspection of the Robert Moses plant's penstocksthe 485 foot tubes that are 24 feet in diameter along the face of the project that carry water from the forebay to the turbine generators; 2) refurbishing the 630-ton crane that enables mechanical work on the turbines; 3) upgrading and digitizing control systems; and building a new back-up control room and 4) overhaul and/or replacement of mechanical components that have reached the end of their operating life.

This first major outage will allow for the installation of new digital controls on the first (one of 13) turbine generator unit and its connections to the control room and the plants substations. Panels in the control room corresponding to the turbine unit also will be digitized as part of the plants overall Control Room upgrade and redesign. The turbine unit outage aligns with another outage for work on NYPAs transmission life extension and modernization program taking place in the plants switchyard.

Thiswill allow new digital controls to be installed on the transformers and circuit breakers corresponding to the upgraded turbine. (This animation describes the digital connections between the generating unit, the control room and the substation). The work on this first unit is part of a design build contract NYPA trustees awarded to Burns and McDonnell earlier this year which includes subcontracts to Emerson and Ferguson Electric of Buffalo. The first-unit outage is expected to last approximately 7 months.

Following the collapse of Niagara Mohawk's Schoellkopf Power Station in 1956, and the elimination of tens of thousands of jobs in the Niagara region and nearly 25 percent of the city's tax base, the Federal Power Commission issued a license in 1957 to the New York Power Authority to redevelop Niagara Falls' hydroelectric power. The Power Authority employed 11,700 workers and within three years, 12 million cubic yards of rock were excavated. The herculean effort led to the construction of a massive main structure that is 1,840 feet long, 580 feet wide and 384 feet high.When the Niagara Power Project produced its first power in 1961, it was the largest hydropower facility in the Western world and President John F. Kennedy called it "an example to the world of North American efficiency and determination." After 60 years of operation and its obtaining a new 50-year federal operating license in 2007, the Niagara Power Project remains the crown jewel of New York's power infrastructure.

NYPA is the largest state public power organization in the nation, operating 16 generating facilities and more than 1,400 circuit-miles of transmission lines. More than 80 percent of the electricity NYPA produces is clean renewable hydropower. NYPA uses no tax money or state credit. It finances its operations through the sale of bonds and revenues earned in large part through sales of electricity.

Check out our free e-newsletters to read more great articles..

Read more from the original source:
NY Power Authority Announces First Milestone of Project to Extend Operating Life of New York's Largest Power Plant - Automation.com

Recommendation and review posted by Bethany Smith

A New Research Published byJCMRon theGlobal Cryonics Technology Market (COVID 19 Version)in various regions to produce more than 200+ page reports. This study is a perfect blend of qualitative and quantifiable information highlighting key market developments, industry and competitors challenges in gap analysis and new opportunities and may be trending in theGlobal Cryonics Technology Market. Some are part of the coverage and are the core and emerging players being profiledPraxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher Scientific, Custom Biogenic Systems, Oregon Cryonics, Alcor Life Extension Foundation, Osiris Cryonics, Sigma-Aldrich, Southern Cryonics,.

Get Free Sample PDF Copy ofGlobal Cryonics Technology MarketReport @:jcmarketresearch.com/report-details/1132891/sample

What we provide inGlobal Cryonics Technology MarketResearch Report?

Get Up to 40 % Discount on Enterprise Copy@jcmarketresearch.com/report-details/1132891/discount

KEY BENEFITS

TheGlobal Cryonics Technology Marketstudy offers a comprehensive overview of the current market and forecasts by 2020-2029 to help identify emerging business opportunities on which to capitalize.

TheGlobal Cryonics Technology Marketreport provides an in-depth review of industry dynamics inCryonics Technology, including existing and potential developments to represent prevailing consumer pockets of investment.

The report provides details concerning key drivers, constraints and opportunities and their effect on theCryonics Technologyreport.

Industry players strategic analysis and industry position in theGlobal Cryonics Technology Market;

The report elaborates on the SWOT analysis and Porters Five Forces model.

The market-study value chain review gives a good view of the positions of the stakeholders.

Note: Please Share Your Budget on Call/Mail We will try to Reach your Requirement@Phone:+1 (925) 478-7203/Email:[emailprotected]

Make the Inquiry for any query before Purchase @:jcmarketresearch.com/report-details/1132891/enquiry

Quantitativedata:

Breakdown of market data by main region & application / end-user

By typeSlow freezing, Vitrification, Ultra-rapid,

Global Cryonics Technology MarketReport-specific sales and growth rates for applicationsAnimal husbandry, Fishery science, Medical science, Preservation of microbiology culture, Conserving plant biodiversity,(historical & forecast)

Global Cryonics Technology MarketProfits by sector and growth rate (history and forecast)

Global Cryonics Technology Marketsize and rate of growth, application and type (Past and Projected)

Global Cryonics Technology MarketSales income, volume and growth rate Y-O-Y (base year)

Qualitative data: Includes factors affecting or influencing market dynamics and market growth. To list some names in related sections

Industry overview

GlobalGlobal Cryonics Technology Marketgrowth driver

GlobalGlobal Cryonics Technology Markettrends

Incarceration

Global Cryonics Technology MarketOpportunity

Market entropy ** [specially designed to emphasize market aggressiveness]

Fungal analysis

Porter Five Army Model

Research Methodology:

Primary Research:

We interviewed various key sources of supply and demand in the course of thePrimary Researchto obtain qualitative and quantitative information related to this report. Main sources of supply include key industry members, subject matter experts from key companies, and consultants from many major firms and organizations working on theGlobal Cryonics Technology Market.

Secondary Research:

Secondary Researchwas performed to obtain crucial information about the business supply chain, the company currency system, global corporate pools, and sector segmentation, with the lowest point, regional area, and technology-oriented perspectives. Secondary data were collected and analyzed to reach the total size of the market which the first survey confirmed.

Customization Available for Following Regions & Country:North America, South & Central America, Middle East & Africa, Europe, Asia-Pacific

Buy Full CopyGlobal Cryonics Technology MarketReport @jcmarketresearch.com/checkout/1132891

The research provides answers to the following key questions:

1) Who are the key Top Key players in the GlobalGlobal Cryonics Technology Market Report?

Following are list of players:Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher Scientific, Custom Biogenic Systems, Oregon Cryonics, Alcor Life Extension Foundation, Osiris Cryonics, Sigma-Aldrich, Southern Cryonics,.

Note: Regional Breakdown & Sectional purchase Available We provide Pie charts Best Customize Reports As per Requirements.

2) Which Are the Main Key Regions Cover in Reports?

Geographically, this report is divided into several main regions, consumption, revenue (million USD) andGlobal Cryonics Technology Marketshare and growth rate in these regions, from 2019 to 2029 (predicted), covering North America, Europe, Asia-Pacific, etc.

3) What is the projected market size & market growth rate for the 2019-2029 periodGlobal Cryonics Technology Marketindustry?

** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so reach our business development executive @[emailprotected]

4) Can I include additional segmentation / market segmentation?

Yes. Additional granularity / market segmentation may be included depending on data availability and difficulty of survey. However, you should investigate and share detailed requirements before final confirmation to the customer.

5) What Is impact of COVID 19 on GlobalGlobal Cryonics Technology Market industry?

Before COVID 19Global Cryonics Technology MarketMarket Size Was XXX Million $ & After COVID 19 Excepted to Grow At a X% & XXX Million $.

TOC for GlobalGlobal Cryonics Technology MarketResearch Report is:

Section 1: Global Market ReviewGlobal Cryonics Technology Market(20132029)

Defining

Description

Classified

Applications

Facts

Chapter 2: Market Competition by Players/Suppliers 2013 and 2019

Manufacturing Cost Structure

Raw Material and Suppliers

Manufacturing Process

Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region (2013-2019)

Sales

Revenue and market share

Chapter 4, 5 and 6: GlobalGlobal Cryonics Technology Marketby Type, Application & Players/Suppliers Profiles (2013-2019)

Continued..

About Author:

JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:JCMARKETRESEARCHMark Baxter (Head of Business Development)Phone:+1 (925) 478-7203Email:[emailprotected]

Connect with us at LinkedIn

Read more from the original source:
Cryonics Technology Market Size & Revenue Analysis | Praxair, Cellulis, Cryologics, Cryotherm, KrioRus - The Think Curiouser

Recommendation and review posted by Bethany Smith

Kim Fundingsland/MDNThis weather radar site that covers the Minot area will be out of service today until Friday, Nov. 20, for scheduled upgrades. The radar is located north of Granville.

GRANVILLE The radar the National Weather Service uses to provide informational coverage and help in compiling forecasts for Minot and the surrounding area is off-line today and will be until at least next Friday. The reason why is to allow for the installation of updated equipment.

The NWS, U.S. Air Force and the Federal Aviation Administration have invested $150-million in a Service Life Extension Program for a network of 159 operational radars in the United States. The radar serving Minot, KMBX WSR-88D, is due for a generator replacement over the next seven days. The project will include fuels tanks and accompanying components.

When completed, the upgrade will support that radars operation during periods of commercial power outages which often occur during times of hazardous weather. The current upgrade is not the last on the schedule. Refurbishment of the pedestal that supports the radar and adjacent equipment shelters will complete the Service Life Extension Program. Those improvements are scheduled for completion in 2023.

Minots weather radar is viewed by many on cell phones, laptops and the like, especially during times of inclement weather such as rain or snow events. While Minots radar will be down during the current maintenance period, the NWS advises weather watchers to monitor adjacent radars at Bismarck, Mayville (Grand Forks), and Glasgow, Montana. The NWS Radar Operation Center is located in Norman, Oklahoma.

Today's breaking news and more in your inbox

See the article here:
Minot's weather radar will be out of service for approximately one week for scheduled upgrades - Minot Daily News

Recommendation and review posted by Bethany Smith

The Global Cryonics Technology Market report has been prepared keeping in mind the need of the customers for the latest information in the Cryonics Technology. With the Global industries recording sharp growth through all the tough financial times, new players are looking to enter into the markets for a larger share of the market. The Global Cryonics Technology Market report has hence been prepared ensuring that the customer gains the maximum and the most accurate information about the Cryonics Technology. The Global Cryonics Technology Market report can aid the customer who could either be a competing player in the market to gain in-depth insights about the Cryonics Technology and plan accordingly, or gain academic knowledge about the market and put it to good use.

Major companies of this report:

PraxairCellulisCryologicsCryothermKrioRusVWRThermo Fisher ScientificCustom Biogenic SystemsOregon CryonicsAlcor Life Extension FoundationOsiris CryonicsSigma-AldrichSouthern Cryonics

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/3415064?utm_source=Ancy

The Global Cryonics Technology Market covers a comprehensive overview of the market in terms of the latest developments. Some key information covered in the Global Cryonics Technology Market report is as follows:Development of the products;Segmentation of the products developed on the basis of stage of development, application, and players among others;Market assessment through segmentation;Product profiles (if applicable);Major players in the Global Cryonics Technology Market.

The Global Cryonics Technology Market report also covers a lot of statistics and visuals for a better representation of the figures about the Cryonics Technology. Every statistic is represented through tables, charts, and other similar mediums for easy and quick consumption of the information by the customer. The report further contains methodology of the research conducted and the development of the report, the coverage in the Global report, and validations of the data in the report by industry experts.

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-cryonics-technology-market-report-2019?utm_source=Ancy

Segmentation by Type:

Slow freezingVitrificationUltra-rapid

Segmentation by Application:

Animal husbandryFishery scienceMedical sciencePreservation of microbiology cultureConserving plant biodiversity

The Global Cryonics Technology Market report is developed for a very niche market and the best brains and professionals have given it their all to prepare the report that will be fulfilling the needs of the customer for an accurate and in-depth insight of the Cryonics Technology. The amount of resources included and the numerous sources consulted for the information presented in this report makes it a must have for those who are looking to make a mark in the Global Cryonics Technology Market.

The Cryonics Technology Market report offers a comprehensive study of the technological growth outlook over time to know the Market growth rates. This report also gives a better understanding about the substantial product components as well as their future. The Cryonics Technology Market report evaluates the Cryonics Technology Market, major issues, production procedures, and their solutions to meet the consumer requirements.

Do Inquiry Before Accessing this Report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/3415064?utm_source=Ancy

About Us :

ABOUT US:Orbis Research (orbisresearch.com) is a single point aid for all your Market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required Market research study for our clients.

Contact Us :

CONTACT US:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

See the article here:
Cryonics Technology Market 2020 to Global Forecast 2023 By Key Companies Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher...

Recommendation and review posted by Bethany Smith

One of the U.S. Navys dedicated adversary squadrons, VFC-12, the Fighting Omars, is about to get a massive increase in capability as it trades its Legacy F/A-18A+ and C/D model Hornets for early examples of the Boeing F/A-18E/F Super Hornet. The War Zone can exclusively reveal that the squadron is expected to make the transition by October 2021. It marks the latest phase in the Navys divestment of original F/A-18A-D variants of the Hornet and the Fighting Omars will be the first Navy aggressor squadron to be fully equipped with the type.

The inclusion of early-batch Super Hornets in VFC-12s adversary mission will alleviate the increasing burden of maintaining older Hornets, many of which have extremely high flight hours, plus it will add some notable enhancements to meet increasing demands for more robust bandit threat training. It follows news that the U.S. Air Force is to similarly enhance its aggressor capabilities by using early examples of the F-35A and younger F-16C/Ds to equip the 65th Aggressor Squadron.

Were hoping that the daily availability of the Super Hornets will make it easier for everyone on the squadron to keep their flight hours up, says VFC-12s Lieutenant Commander Ian Bro Hutter. The Super Hornet also carries more fuel, so it can stay airborne longer, which will also reduce the burden in terms of the actual number of sorties we have to fly, he adds.

VFC-12, which is home-based at Naval Air Station Oceana in Virginia, and uses the radio callsign and nickname Ambush, looks set to receive some of the oldest Super Hornets previously in use by the fleet. These are examples that were originally assigned to Strike Fighter Squadron (VFA) 27 Royal Maces since 2004. This unit, assigned to Carrier Air Wing Five in Japan, swapped its original Block I F/A-18Es for new Block II examples.

Super Hornets will herald a welcome boost in the way the Fighting Omars fly their critical fleet support missions. Its not currently clear if the jets destined for VFC-12 will be modified under the Boeing Service Life Modernization life extension program, which you can read more about here.

U.S. Navy

VFC-12 received F/A-18Cs in recent years to replace its F/A-18A+ Hornets.

Transitioning VFC-12 to the Super Hornet is the latest in a succession of moves by the U.S. Navy to remove the 1980s-era Legacy Hornets from its inventory. It also reflects a need to evolve adversary technology and employ more advanced training techniques to meet growing threats abroad.

While the Marine Corps continues to operate the Hornet, original A-D models have all beenretired from the front line Navy units, and the Blue Angels flight demonstration team is also now receiving Super Hornets, as well. Along with VFC-12, the River Rattlers of VFA-204, the U.S. Naval Test Pilots School (TPS), and the Naval Fighter Weapons School, better known as Topgun, are the only remaining Navy units that still fly the Legacy Hornet.

Lieutenant Commander Hutter spoke to The War Zone while deployed for a month with VFC-12 to Naval Air Station Key West, in Florida, supporting unit-level work-ups for fleet Super Hornet squadrons under the Strike Fighter Advanced Readiness Program, known as SFARP. One of the Fighting Omars' main taskings is to provide high-end red air adversary threat presentations to fleet aviators in order to help them prepare for combat deployments.

SFARP typically involves two fleet squadrons coming here for two weeks. They then leave and another two new squadrons rotate in here, Hutter explains. SFARP is an initial phase in deployment work up preparations for Carrier Air Wing (CVW) strike fighter squadrons.

If you break down our level of priorities at VFC-12, the highest would be what we call core events, which are related to the Optimized Fleet Response Plan [OFRP]. This starts about a year before a carrier air wing deploys. The first step of this is SFARP, which is squadron-level tactics, and is what we primarily support, Hutter explains. Squadrons typically conduct these events at Key West for air-to-air SFARP, and NAS Fallon for air-to-surface phases. VFC-12 provides threat aircraft presentations to give the fleet pilots a credible adversary to contend with during these periods.

U.S. Navy/MCS2C Brian Morales

Super Hornets detached to Boca Chica Field, NAS Key West, during SFARP.

We also support COMPTUEX [Composite Training Unit Exercises] in the latter part of the work-up, right as the units get ready to deploy on the carrier as an air wing. This typically means we deploy to NAS Jacksonville, Florida, for the East Coast, or to NAS North Island, California, for the West Coast. So we have four main detachment locations for us. SFARP and COMPTUEX trump everything else if theres a requirement for us to support either of those, we will drop everything and go.

Next down the priority list is a relatively new mission known as Legacy Transition Training, or LTT. We started this last year, says Hutter, explaining how LTT is a training role the squadron picked up to convert existing aviators to fly the Legacy Hornet after the designated Fleet Replacement Squadron (FRS), VFA-106, the Gladiators, ceased flying training for Hornets in October 2019. VFC-12 now supports the pilot and maintainer training requirement to supply the handful of units in the Navy that still operate the F/A-18A-D.

Its going to be relatively short-lived, because we are scheduled to be transition-complete to the Super Hornet this time next year [November 2021], says Hutter. LTT is for staff instructors going to fly the C/D at Topgun, at VFA-204, or at TPS. We do their training and last year we had over 50 people come through for the five hours of flying training to get the charlie qual.

The Omars also provide red air training for the Oceana-based units in what the squadron refers to as fleet support but Hutter acknowledges this third tier responsibility is, unfortunately, on an as-available basis due to the myriad of more pressing demands.

Jamie Hunter

VFC-12 provides "fleet support" for home-based training from NAS Oceana when schedules allow.

Like VFC-13, the Fighting Saints, at NAS Fallon, and VFC-111, the Sundowners, at NAS Key West, both of which fly the F-5N/F Tiger II, and aforementioned River Rattlers at Joint Reserve Base New Orleans, Louisiana, VFC-12 is part of the Tactical Support Wing (TSW), a wing belonging to the Naval Reserves. The U.S. Navy closed down its active-duty adversary squadrons in the mid-1990s, and in doing so (aside from Topgun instructors), it handed responsibility for red air over to the Reserves.

Hutter is the only Weapons Systems Officer (WSO) currently on staff at VFC-12 and, like most of the aircrew here, he is a highly experienced Topgun graduate. Everyone here is technically a full-time reservist. Our current Skipper is full-time support staff, we also have four full-time support department heads. As far as pilots go, the rest are Selected Reservists [SELRES]. This means they have regular jobs away from the squadron, but provide a certain number of days per month. VFC-12s maintainers are all U.S. Navy sailors, a mix of active-duty, full-time support, or the more traditional reservists, unlike the two F-5 squadrons, which have their maintenance undertaken by contractors.

U.S. Navy/Danette Baso Silvers

An F-5N of VFC-111 "Sundowners."

The great thing about VFC-12 is that we get to hand pick our staff for the most part. All our SELRES pilots are Topgun graduates with the blue patch. Probably 80% of our guys have gone through that syllabus and the experience here provides the ability to quickly transition between missions to lead a flight at the last minute. Everyone in the squadron is of a very high caliber, and the importance of having that network of people, who can coordinate pretty much anything, cannot be overstated.

The coveted blue patch is awarded to students who complete the main Topgun course, which is dedicated to friendly (Blue Air) tactics. Topgun also oversees a Navy adversary course that results in a graduate being awarded a red Topgun adversary patch. In order to lead a core OFRP event, you have to be a Level 4 adversary, explains Hutter. Individuals who graduate from the Topgun red air course are designated as a Level 5 adversary, the highest standard, and a training officer can then train Level 4 adversaries at the respective VFC units.

Jamie Hunter

The red Topgun adversary patch.

Hutter elaborates that Level 4 is essentially an adversary mission commander. It means you can provide a high-quality threat representation and meet fighter training objectives in threat simulation. It also means that you are able to manage a lot of airplanes in the airspace.

VFC-12/13/111 and VFA-204 all send pilots through the red class at Topgun, then they come back to the squadron as training officers and qualify us. We have constant discussions with Topgun and we fight based on how they assess current threat capabilities. For VFC-12 specifically, our work is all about that high-end threat replication. When the fleet squadrons need a more benign 'radar reflector' for beyond visual range type engagements, they tend to use the F-5s. Those guys also support the FRS training units, but we typically dont.

SFARP is managed by both the East and West Coast Strike Fighter Weapons Schools and it is designed to offer the most challenging division [4-ship] level fleet tactics. Were doing that here at Key West right now; four blue air fleet Hornets against up to 20 bandits. Theres no contract red air at this SFARP, but its not unheard of for them to be here. As a squadron, we have 11 Hornets here now, and we are flying three 'gos' a day.

VFC-12 offers the Navys highest level of threat replication, and its not just about a generic presentation. We study threat pilot tactics and how threat nations operate, says Hutter. We understand how threat nations of interest operate, this isnt red air between fellow JOs [Junior Officers]. Our threats are very specific. In SFARP its always Russian or Chinese aircraft. Its not targeted at those countries, but they just have the most capable airplanes. So, its targeted at those top tier airframes.

Jamie Hunter

A VFC-12 F/A-18D in "splinter" scheme.

Describing a typical SFARP mission out of NAS Key West, Lieutenant Commander Hutter says: You take off over the turquoise sea and fly over fishing boats, and do some cloud dodging. We fly in the Whiskey 174 range complex, which essentially runs between Key West and out towards Texas. The bandits flow out to the west, and the fighters start in the east. We need to get anywhere between 8 and 20 adversary aircraft together. Everyone checks in and we start our plan to confuse the fighters. The hardest part is keeping track of who is who.

We send a pilot to the TCTS [Tactical Combat Training System] range control center and they can work with the Range Training Officers on the radio to help ensure the objectives are met. Hutter clarifies that the use of a Ground Controlled Intercept (GCI) controller very much depends on how much is going on. They are there to provide additional situational awareness on the evolving skirmish. With the potential of over 20 fighters merging, the range/training safety officers are there to help avoid a collision. The VFC F-5s are now flying with Red Net. This works with the TCTS and, on an iPad in the cockpit, they can now see the whole air picture. Its a capability that VFC-12 expects to build upon when it receives its Super Hornets thanks to their Multifunction Information Distribution System (MIDS).

We use a standard height block structure [broken down within each 10,000ft block]. The blue air fighters are usually in the 5,000-9,000ft block and the bandits are 0-4,000ft. The higher and faster the shooters fly, the better the kinematics of the missiles. If we are up at 45,000ft and flying at Mach 1.2 indicated airspeed, we present a much harder problem for them. In the more complex exercises like Red Flag, you might hold for 30 minutes, fly towards the Blue guys, get told youre dead, and never see another jet. The great thing about what we do in our division level tactics is that we can get a lot closer.

U.S. Navy/MCS2C Brian Morales

VFA-204 "River Rattlers" Hornets taxi out at Key West during an SFARP.

Merging and getting into a close turning fight very much depends on the mission that we are supporting. The fighters have some missions where their acceptable level of risk is low, so we, therefore, have very few merges. In fact, they will avoid the merge at all costs, preferring to run away. The higher their acceptable level of risk for the mission is, the more merges we will have. Well have flights where everybody merges! Typically thats when theres a lot of electronic attack out there, a lot of bandits and a lot of fighters. The higher the risk their mission is, the more willingness they have to go to the merge. Unless there are Raptors joining the fight. If Raptors are there, we never get to the merge, smiles Hutter, emphasizing the U.S. Air Force fighters prowess in fighting at long range.

Approaching the merge, if we don't see the fighters then we will be at the bottom of our block height, and they will be at the top of theirs. That gives us a 1,000ft avoidance. If we see them, and were high on situational awareness, we can see everyone visually all wingmen and tally all the fighters then we are clear to come out of our block [and start Basic Fighter Maneuvers, BFM, aka dogfighting]. The contract red air providers are not permitted contractually to dogfight with fleet aircraft, and are often limited to level 180 degree turns. The Navy contract for contract air support does not allow them to BFM, Hutter confirms.

Red air tactics are so advanced now. As a JO [junior officer] I remember the bandits flew slow, they stayed level, and maneuvered very little. Today, as red air, we are making sure we are as testing to the fighters as possible. Its definitely not easy to do anymore. We are being asked to give the fighters increasingly robust presentations.

Jamie Hunter

Topgun instructors currently fly a mix of Hornets and Super Hornets in the adversary role.

As fleet units field increasing capabilities, the Navy adversaries are having to up their game. Currently, the use of simulation and synthetic training has not found its way into the VFC-12 world its all about live flying. Every day we see contractors working to make simulations better. Until its really good, seamless, we arent going to use it. In the workups towards SFARP, there is a simulator portion where we sit at the consoles and direct the red air simulation for the fighters. Until the synthetic training is seamless, it can be negative training or a waste of time if its not as good as the real thing.

Hutter says VFC-12 has seen some change with the advent of the F-35 Lightning II, but mainly in the realm of security. There are currently no separate training objectives for the F-35 than there are for the Super Hornet we test them the same way, but that will change Im sure. We are here to be threat representative and I dont think any threat country knows how to truly deal with stealth technology yet, but it takes a long time for feedback to get to us.

Having enjoyed a subtle upgrade by trading some of its F/A-18As for F/A-18C/Ds a couple of years ago as they were handed down from fleet units, Hutter says the move to the Super Hornet will have significant benefits.

Jamie Hunter

VFC-12 is expected to receive early Block I F/A-18E/Fs.

The cost per flight hour of operating just a few units of C/D Hornets is significant, and the Navy wants to remove them from the inventory fast, consolidating on the Super Hornet. This means Topgun is likely to lose its handful of adversary Hornets flown by its instructors, meaning it might receive additional adversary Rhinos. In addition, the River Rattlers too are set to convert to a new type. Rumors have said this could see the VFA-204 receive secondhand F-16s, but nothing is publicly confirmed.

For VFC-12, its new jets will be pre-Lot 25 Block I standard Super Hornets. Examples from Lot 25 and beyond are Block II standard aircraft that use high-order language (HOL) software and are equipped with the AN/APG-79 Active Electronically Scanned Array (AESA) radar. F/A-18E/Fs prior to Lot 25 use X-series software, which mirrors that of the Legacy Hornet. Hutter explains that a Super Hornet fleet all equipped with the Block I's AN/APG-73 mechanically scanned array radar and MIDS will be a huge advantage over the older Hornets. The current VFC-12 Hornets have a mix of AN/APG-65 and -73 radars.

Some of our missions get really complicated, and in our current Hornets we might have low situational awareness. Its not so much about being as lethal, here it's also about herding a lot of cats, says Hutter, who adds that its routine for Ambush aircrews to spend too much time being distracted by troubleshooting radar issues, and with no MIDS data link it makes the job of threat presentation work far more difficult while the pilots are busy trying to work out who is who, and where everyone is.

VFC-12 will not be the first to use the Super Hornet in the adversary role, with Topgun already operating a handful of early examples. VFC-12 should receive its first Rhino in February, with a dozen due to be on the flight line by October as it completes a staggered transition, which will enable it to continue its important mission in the meantime.

U.S. Navy/VFC-12

Proposed VFC-12 schemes designed to represent a Russian Su-57 and a Chinese J-11.

According to Hutter, the Super Hornets will give Ambush aircrews a better ability to detect targets at range, but also they will be harder to detect themselves, due to some of the low observable design features of the Super Hornet. The Hornet is easier to see than a Super Hornet, he says. There are negatives though. Seeing a different aircraft at the merge is helpful for fleet aviators. Most squadrons only ever see Super Hornets when theyre fighting.

To make its Super Hornets look like realistic bandits, some remarkable special adversary schemes are being lined up for the new VFC-12 jets. Painting these aircraft differently compared to standard gray fleet jets will be more important than ever to help distinguish the bad guys. With a host of incredible suggested Russian and Chinese liveries on the drawing board, VFC-12 is well placed to retain its position flying some of the coolest-looking jets in the Navy, as well as upping its game to retain its standing as the Navys premier adversary squadron. We will be featuring a full set of the proposed VFC-12 Super Hornet schemes as a follow up to this exclusive story very soon.

Regardless of how they end up being painted, the Super Hornets will breathe new life into the Fighting Omars and will go a long way when it comes to keeping fleet pilots ready for any potential threats they could encounter while cruising some of the world's tensest waters.

Contact the editor: Tyler@thedrive.com

Read more:
Inside The Navy's Top Aggressor Squadron That Is About To Trade Its Hornets For Super Hornets - The Drive

Recommendation and review posted by Bethany Smith

LOS ANGELES, United States: The report is an all-inclusive research study of the global Antioxidant Supplement market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Antioxidant Supplement market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Antioxidant Supplement report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2077879/global-japan-antioxidant-supplement-market-insights

In addition, market revenues based on region and country are provided in the Antioxidant Supplement report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Antioxidant Supplement market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Antioxidant Supplement market are mapped by the report. With the help of this report, the key players of the global Antioxidant Supplement market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Antioxidant Supplement market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Antioxidant Supplement market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Antioxidant Supplement Market Research Report: NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension

Types: Medical GradeFood Grade

Applications: MedicalFoodCosmetics

The Antioxidant Supplement Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Antioxidant Supplement market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Antioxidant Supplement market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2077879/global-japan-antioxidant-supplement-market-insights

Table of Contents:

1 Study Coverage1.1 Antioxidant Supplement Product Introduction1.2 Market Segments1.3 Key Antioxidant Supplement Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Antioxidant Supplement Market Size Growth Rate by Type1.4.2 Medical Grade1.4.3 Food Grade1.5 Market by Application1.5.1 Global Antioxidant Supplement Market Size Growth Rate by Application1.5.2 Medical1.5.3 Food1.5.4 Cosmetics1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Antioxidant Supplement Market Size, Estimates and Forecasts2.1.1 Global Antioxidant Supplement Revenue 2015-20262.1.2 Global Antioxidant Supplement Sales 2015-20262.2 Global Antioxidant Supplement, Market Size by Producing Regions: 2015 VS 2020 VS 20262.3 Antioxidant Supplement Historical Market Size by Region (2015-2020)2.3.1 Global Antioxidant Supplement Retrospective Market Scenario in Sales by Region: 2015-20202.3.2 Global Antioxidant Supplement Retrospective Market Scenario in Revenue by Region: 2015-20202.4 Antioxidant Supplement Market Estimates and Projections by Region (2021-2026)2.4.1 Global Antioxidant Supplement Sales Forecast by Region (2021-2026)2.4.2 Global Antioxidant Supplement Revenue Forecast by Region (2021-2026)

3 Global Antioxidant Supplement Competitor Landscape by Players3.1 Global Top Antioxidant Supplement Sales by Manufacturers3.1.1 Global Antioxidant Supplement Sales by Manufacturers (2015-2020)3.1.2 Global Antioxidant Supplement Sales Market Share by Manufacturers (2015-2020)3.2 Global Antioxidant Supplement Manufacturers by Revenue3.2.1 Global Antioxidant Supplement Revenue by Manufacturers (2015-2020)3.2.2 Global Antioxidant Supplement Revenue Share by Manufacturers (2015-2020)3.2.3 Global Antioxidant Supplement Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Antioxidant Supplement Revenue in 20193.2.5 Global Antioxidant Supplement Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Antioxidant Supplement Price by Manufacturers3.4 Global Antioxidant Supplement Manufacturing Base Distribution, Product Types3.4.1 Antioxidant Supplement Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Antioxidant Supplement Product Type3.4.3 Date of International Manufacturers Enter into Antioxidant Supplement Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Antioxidant Supplement Market Size by Type (2015-2020)4.1.1 Global Antioxidant Supplement Sales by Type (2015-2020)4.1.2 Global Antioxidant Supplement Revenue by Type (2015-2020)4.1.3 Antioxidant Supplement Average Selling Price (ASP) by Type (2015-2026)4.2 Global Antioxidant Supplement Market Size Forecast by Type (2021-2026)4.2.1 Global Antioxidant Supplement Sales Forecast by Type (2021-2026)4.2.2 Global Antioxidant Supplement Revenue Forecast by Type (2021-2026)4.2.3 Antioxidant Supplement Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Antioxidant Supplement Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)5.1 Global Antioxidant Supplement Market Size by Application (2015-2020)5.1.1 Global Antioxidant Supplement Sales by Application (2015-2020)5.1.2 Global Antioxidant Supplement Revenue by Application (2015-2020)5.1.3 Antioxidant Supplement Price by Application (2015-2020)5.2 Antioxidant Supplement Market Size Forecast by Application (2021-2026)5.2.1 Global Antioxidant Supplement Sales Forecast by Application (2021-2026)5.2.2 Global Antioxidant Supplement Revenue Forecast by Application (2021-2026)5.2.3 Global Antioxidant Supplement Price Forecast by Application (2021-2026)

6 Japan by Players, Type and Application6.1 Japan Antioxidant Supplement Market Size YoY Growth 2015-20266.1.1 Japan Antioxidant Supplement Sales YoY Growth 2015-20266.1.2 Japan Antioxidant Supplement Revenue YoY Growth 2015-20266.1.3 Japan Antioxidant Supplement Market Share in Global Market 2015-20266.2 Japan Antioxidant Supplement Market Size by Players (International and Local Players)6.2.1 Japan Top Antioxidant Supplement Players by Sales (2015-2020)6.2.2 Japan Top Antioxidant Supplement Players by Revenue (2015-2020)6.3 Japan Antioxidant Supplement Historic Market Review by Type (2015-2020)6.3.1 Japan Antioxidant Supplement Sales Market Share by Type (2015-2020)6.3.2 Japan Antioxidant Supplement Revenue Market Share by Type (2015-2020)6.3.3 Japan Antioxidant Supplement Price by Type (2015-2020)6.4 Japan Antioxidant Supplement Market Estimates and Forecasts by Type (2021-2026)6.4.1 Japan Antioxidant Supplement Sales Forecast by Type (2021-2026)6.4.2 Japan Antioxidant Supplement Revenue Forecast by Type (2021-2026)6.4.3 Japan Antioxidant Supplement Price Forecast by Type (2021-2026)6.5 Japan Antioxidant Supplement Historic Market Review by Application (2015-2020)6.5.1 Japan Antioxidant Supplement Sales Market Share by Application (2015-2020)6.5.2 Japan Antioxidant Supplement Revenue Market Share by Application (2015-2020)6.5.3 Japan Antioxidant Supplement Price by Application (2015-2020)6.6 Japan Antioxidant Supplement Market Estimates and Forecasts by Application (2021-2026)6.6.1 Japan Antioxidant Supplement Sales Forecast by Application (2021-2026)6.6.2 Japan Antioxidant Supplement Revenue Forecast by Application (2021-2026)6.6.3 Japan Antioxidant Supplement Price Forecast by Application (2021-2026)

7 North America7.1 North America Antioxidant Supplement Market Size YoY Growth 2015-20267.2 North America Antioxidant Supplement Market Facts & Figures by Country7.2.1 North America Antioxidant Supplement Sales by Country (2015-2020)7.2.2 North America Antioxidant Supplement Revenue by Country (2015-2020)7.2.3 U.S.7.2.4 Canada

8 Europe8.1 Europe Antioxidant Supplement Market Size YoY Growth 2015-20268.2 Europe Antioxidant Supplement Market Facts & Figures by Country8.2.1 Europe Antioxidant Supplement Sales by Country8.2.2 Europe Antioxidant Supplement Revenue by Country8.2.3 Germany8.2.4 France8.2.5 U.K.8.2.6 Italy8.2.7 Russia

9 Asia Pacific9.1 Asia Pacific Antioxidant Supplement Market Size YoY Growth 2015-20269.2 Asia Pacific Antioxidant Supplement Market Facts & Figures by Country9.2.1 Asia Pacific Antioxidant Supplement Sales by Region (2015-2020)9.2.2 Asia Pacific Antioxidant Supplement Revenue by Region9.2.3 China9.2.4 Japan9.2.5 South Korea9.2.6 India9.2.7 Australia9.2.8 Taiwan9.2.9 Indonesia9.2.10 Thailand9.2.11 Malaysia9.2.12 Philippines9.2.13 Vietnam

10 Latin America10.1 Latin America Antioxidant Supplement Market Size YoY Growth 2015-202610.2 Latin America Antioxidant Supplement Market Facts & Figures by Country10.2.1 Latin America Antioxidant Supplement Sales by Country10.2.2 Latin America Antioxidant Supplement Revenue by Country10.2.3 Mexico10.2.4 Brazil10.2.5 Argentina

11 Middle East and Africa11.1 Middle East and Africa Antioxidant Supplement Market Size YoY Growth 2015-202611.2 Middle East and Africa Antioxidant Supplement Market Facts & Figures by Country11.2.1 Middle East and Africa Antioxidant Supplement Sales by Country11.2.2 Middle East and Africa Antioxidant Supplement Revenue by Country11.2.3 Turkey11.2.4 Saudi Arabia11.2.5 U.A.E

12 Company Profiles12.1 NOW12.1.1 NOW Corporation Information12.1.2 NOW Description and Business Overview12.1.3 NOW Sales, Revenue and Gross Margin (2015-2020)12.1.4 NOW Antioxidant Supplement Products Offered12.1.5 NOW Recent Development12.2 Vibrant Health12.2.1 Vibrant Health Corporation Information12.2.2 Vibrant Health Description and Business Overview12.2.3 Vibrant Health Sales, Revenue and Gross Margin (2015-2020)12.2.4 Vibrant Health Antioxidant Supplement Products Offered12.2.5 Vibrant Health Recent Development12.3 AST R-ALA12.3.1 AST R-ALA Corporation Information12.3.2 AST R-ALA Description and Business Overview12.3.3 AST R-ALA Sales, Revenue and Gross Margin (2015-2020)12.3.4 AST R-ALA Antioxidant Supplement Products Offered12.3.5 AST R-ALA Recent Development12.4 GNC12.4.1 GNC Corporation Information12.4.2 GNC Description and Business Overview12.4.3 GNC Sales, Revenue and Gross Margin (2015-2020)12.4.4 GNC Antioxidant Supplement Products Offered12.4.5 GNC Recent Development12.5 Jarrow Formulas12.5.1 Jarrow Formulas Corporation Information12.5.2 Jarrow Formulas Description and Business Overview12.5.3 Jarrow Formulas Sales, Revenue and Gross Margin (2015-2020)12.5.4 Jarrow Formulas Antioxidant Supplement Products Offered12.5.5 Jarrow Formulas Recent Development12.6 Life Extension12.6.1 Life Extension Corporation Information12.6.2 Life Extension Description and Business Overview12.6.3 Life Extension Sales, Revenue and Gross Margin (2015-2020)12.6.4 Life Extension Antioxidant Supplement Products Offered12.6.5 Life Extension Recent Development12.11 NOW12.11.1 NOW Corporation Information12.11.2 NOW Description and Business Overview12.11.3 NOW Sales, Revenue and Gross Margin (2015-2020)12.11.4 NOW Antioxidant Supplement Products Offered12.11.5 NOW Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Antioxidant Supplement Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Antioxidant Supplement Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

In Order to place the Purchase Query Click Here: https://www.qyresearch.com/settlement/pre/2077879/global-japan-antioxidant-supplement-market-insights

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Read more here:
Antioxidant Supplement Market Bolstered by Emerging New Advancements, Says QYR | NOW, Vibrant Health, AST R-ALA, GNC - The Think Curiouser

Recommendation and review posted by Bethany Smith

A casual viewer can soak in Blade Runner, more or less accept it as a visually breathtaking sci-fi action tale, and walk away satisfied. Deckard is the protagonist, played by an actor we recognize from previous heroic roles. He kills the criminals he's told to kill at the beginning of the story, and then he gets the girl. From that perspective, Blade Runner follows a familiar, comforting formula.

But wait. Deckard is ordered to execute Roy Batty (Rutger Hauer) and all of his friends on sight without any due process, for the sole crime of existing on a planet they're not supposed to be on. That doesn't quite seem fair, does it?

Why can't Roy sue the Tyrell Corporation for a life extension? Why can't he hire an attorney to help him make a case before a jury of his peers? Well, he can't because replicants don't have rights. Under the law, they're not considered people. But who gets to decide who counts as a person?

In this case, humans function as a metaphorical majority that, by the mere unchallenged virtue of being the majority, dictates the norm. This social paradigm leaves those who fall outside the norm replicants, in this case open to exploitation and abuse. It's almost as if Deckard, by working to uphold unjust laws, is a trooper in some sort of empire, and Roy is rebelling against that empire. In fact, Roy is part of a whole entire alliance of rebels. Hmmmm.

Follow this link:
Why Blade Runner is the best sci-fi movie of all time - Looper

Recommendation and review posted by Bethany Smith

(CNN) -- For the transgender people who seek it, gender-affirming hormone therapy can be lifesaving. But if they're uninsured or their insurance won't cover it, some bypass the health care system entirely to get the care they need.

Around 75,000 transgender Americans are likely using hormones that weren't prescribed -- close to 1 in 10 of the estimated 1.4 million transgender adults in the US -- says a study published this month in the Annals of Family Medicine.

Beyond the health risks of using nonprescription hormones, the findings indicate extensive barriers to care transgender Americans face, lead author Dr. Daphna Stroumsa told CNN.

"Trans people face a multitude of cultural and structural hurdles in staying safe and healthy," said Stroumsa, a clinical lecturer in the University of Michigan's Department of Obstetrics and Gynecology who specializes in LGBTQ health care. "We need to streamline care. We don't need to put barriers between patients and providers."

Using data from the US Transgender Survey, a sample of almost 28,000 trans Americans from the National Center for Transgender Equality, the study focused on two groups: Uninsured trans people and trans people whose insurance company denied their claims for gender-affirming hormones. Both groups were more likely to seek out nonprescription hormones than insured transgender people, according to the study.

Trans Americans are more likely to be uninsured than the general population -- about 15.5% of respondents in the US Transgender Survey compared to 12.8% of US adults. And among uninsured respondents, around 21% said their insurance claims for gender-affirming care had been denied, according to the study.

About 84% of respondents to the US Transgender Survey said they wanted gender-affirming hormones, but around 55% of them were actually taking hormones. Among all respondents taking hormones, more than 9% of them said they were using nonprescribed hormones.

On one hand, the fact that some trans people circumvent the healthcare system to access gender-affirming care shows their "resilience," Stroumsa said. But from a physician's perspective, that's a sign of failure, they said.

"This indicates that we have a problem in getting trans people lifesaving medication," they said.

Hormone therapy can be expensive out of pocket -- often around $30 a month, according to a 2013 CNN piece, though that amount can vary. It can also be dangerous when not regulated by a physician, Stroumsa said. Some hormone therapies can increase risk of heart problems or stroke. And without a doctor to monitor the dosage and components of the hormones they're receiving, trans patients may experience unforeseen health issues.

Mounting evidence shows that accessing gender-affirming health care can be lifesaving for trans people who seek it. UCLA's Williams Institute, a think tank that focuses on LGBTQ legal issues, reported that a lack of gender-affirming care likely contributed to high percentages of suicidal thoughts among transgender Americans.

And though it's illegal for most insurance companies to discriminate against trans Americans, 30 states permit health insurance plans to exclude some trans health services, NPR reported in 2019.

Stroumsa said insurance companies that cover such procedures often ask patients to provide proof that procedures or treatments are necessary. For example, a trans man's insurers may require him to provide two signed letters from mental health care providers when he seeks a gender-affirming hysterectomy, they said.

Insurance is just one hurdle trans people face in getting care. There's the discrimination they often face from physicians and health care providers who refuse them care or misstate their gender, and higher rates of homelessness and joblessness -- all likely reasons why some trans people bypass the health care system altogether.

"Health care systems and physicians and health care providers have so often failed trans people, either with direct discrimination or ignorance of trans people's health care needs," Stroumsa said. "We need to fix that."

One of the ways physicians can start to mend those gaps, they said, is by including trans people in the agenda-setting process and taking their needs into account when setting insurance policies. Some major medical associations, including the American Academy of Family Physicians, have announced their support for insurance coverage of gender-affirming care. More voices in support of gender-affirming health care coverage could remove at least one obstacle.

See the original post here:
Almost 1 in 10 transgender Americans use nonprescribed hormones because they're uninsured or insurance won't cover the cost - CBS46 News Atlanta

Recommendation and review posted by Bethany Smith

Dr. Cherie Worford speaks about the resources available to the transgender community through the Colorado State University Health Network. (Matt Tackett | The Collegian)

Medical care for transgender and gender nonbinary people varies in accessibility and practice throughout the country.

At Colorado State Universitys Health Network, its become more mainstream.

Dr. Cherie Worford is the clinical supervisor of the Womens and Gender Care Clinic at CSUs Health Network and a medical physician subtrained in obstetrics and gynecology.

One of Worfords primary duties is to aid transgender and gender nonbinary people interested in medically transitioning via hormone injections.

Medical transition is for patients who are identifying as transgender and are looking to take medications to potentially cause some external changes, aligning internal gender identity with external gender (appearance), Worford said.

We try to be as straightforward as possible. Its available, were here to do it, were happy to see you. Let us know how we can help, all without making it an overly medicalized situation.Dr. Cherie Worford, CSU Womens and Gender Care Clinic clinical supervisor, medical physician

According to Worford, the general process begins with an introductory meeting in which the doctor and patient go over the patients general health history and things that could potentially affect them being on medications.

This is followed by a discussion of the patients history with gender dysphoria, internal distress caused when an individuals gender identity differs from the sex they were assigned at birth, she explained.

During this conversation, the doctor and patient discuss what aspects of their gender identity they find dysphoric and what the patient hopes to gain from being prescribed hormones, Worford said.

This includes short- and long-term goals, where on the gender spectrum the patient wants to transition toward and what they may want to accomplish overall by medically transitioning, she said.

CSU in general, as most clinics now which is good run on whats called the informed consent model, Worford said.

This model requires medical professionals to educate their patients on what medical procedures are and the benefits and the risks involved, according to Worford.

Due to this practice, patients know what it is they want and the effects the medical practices can have prior to consenting to taking medications, she said.

I essentially talk to patients about what this (process) is, what hormones are, this is what they do, these are the benefits we see, these are the potential risks (and seeing if people are) still interested in doing it, Worford said.

According to Worford, medical professionals dont have to be involved in counseling nor do hormone suppliers require the approval of a mental health provider for a patient to qualify for hormones.

Before the implementation of the Health Networks current practices, a patient had to pass certain criteria to be approved for any method of medical transitioning. They had to live as their desired and identified gender for a year before they could get approved to transition. This came with a lot of psychological and social safety issues associated with it, Worford said.

According to Worford, some patients come in the first day, and they know exactly what they want. For others, it takes a couple appointments and consultations for them to think things through and decide if they want to proceed toward a hormone treatment or if they arent ready to take that step yet.

We try to be as straightforward as possible, Worford said. Its available, were here to do it, were happy to see you. Let us know how we can help, all without making it an overly medicalized situation.

For a full gender transition, from start to finish, the process can take up to three to five years depending on how far into the transition the patient would like to go, according to Worford.

In transgender women, breast development may take a long time, while in transgender men, their voice may deepen quickly but their facial and body hair growth can take longer, she said.

For gender nonbinary individuals or those whod like an androgynous appearance, it may take less time in total, Worford explained.

We dont question their motives. Its a legitimate procedure, and we are providing a service without judgement. -Dr. Paul Steinwald, Denver plastic surgeon

Prescribed hormone doses vary for each person and where on the gender spectrum theyd like to be. An increase in dosage doesnt necessarily speed up the process. For some, it simply increases the symptoms, Worford said.

It can be a slow process, Worford said. I tell people its a similar concept to puberty. For a majority of us, puberty does not happen overnight. Most of us didnt really enjoy it. Its like a second puberty.

Jill Vesty is a family nurse practitioner who works alongside Worford at the CSU Health Network. She aids in educating patients on the process of taking hormones, helping them decide what steps to take on their journey through transitioning.

Vesty has worked with the Health Network for 10 years and was on staff when it started to implement transgender health care.

I care about people, I care about society, Vesty said. I think everybody deserves health care, and I want to help people access it.

According to Vesty, the CSU Health Network has largely mirrored the type of care that has become more normalized throughout the United States for this community.

A type of health care that was once thought to be specialized, transgender care has become more incorporated into general, primary care, Vesty explained.

I think its great when a transgender student can come in with any number of medical issues, and the same clinician can manage all of those medical issues, Vesty said. It increases access if you have more general family practitioners to provide this care as part of their routine.

According to Vesty, this improves awareness across the spectrum and makes resources more widely known. This allows individuals who are on their way to transitioning to become aware of what is available, she said.

Vesty said the Health Network does not provide specialty care like plastic surgery. However, they are always able to recommend services that are both financially and regionally accessible for their patients.

Dr. Paul Steinwald is a plastic surgeon with the Center for Cosmetic Surgery, located in Denver. A specialty to his practice is his chest masculinization procedure, otherwise known as top surgery.

According to Steinwald, he is one of the few plastic surgeons that, when removing breasts, will try to keep the breast attached, specifically the nipple.

While this is considered to be a more difficult procedure that has risks, Steinwald said it is more likely to retain sensation in the area.

While other surgeons generally take the nipple off and graft it back on, Steinwald prefers to only do that for individuals with larger breasts, size DD or higher.

It heals better than a graft ever would, Steinwald said. And you can adjust it or revise it later with everything still attached, versus grafting.

According to Steinwald, its really about how the patient will scar. If the nipple looks good two weeks after the procedure, then the patient is in a good place. Otherwise, the need for revision would be considered.

Overall, its a very well-tolerated procedure with a 95% success rate for nipple survival, and thats key, Steinwald said.

Steinwald has been working with the transgender community for the majority of his career, his first experience occurring in 2002.

Its a very wonderful population of patients, Steinwald said. I think they should be treated like everyone else, with good, safe care and respect.

His staff has reported positively when working with individuals within the community.

We dont question their motives, Steinwald said. Its a legitimate procedure, and we are providing a service without judgement.

Dorina Vida can be reached at news@collegian.com or on Twitter @simply_she_.

See the original post:
Transgender health care: Shifting to the conventional The Rocky Mountain Collegian - Rocky Mountain Collegian

Recommendation and review posted by Bethany Smith

With more than 11 million cases of COVID-19 in the United States and few treatments available, its no wonder that a study suggesting melatonin may treat or even prevent the coronavirus has gained attention. But alluring as it is to think that a sleep aid sold at most drugstores can cure this virus, experts tell Yahoo Life that those believing its a silver bullet are significantly off the mark.

Its a gigantic leap, says Dr. Ryan Marino, an emergency room physician and medical toxicologist in Ohio. This finding may certainly be worth studying further, but it will not change how I treat my patients or myself, and I would urge everyone caution in interpreting these headlines.

The study was published in the journal PLOS Biology this week, accompanied by a press release from the Cleveland Clinic, where it was conducted, that said that researchers had used data to identify melatonin as a possible treatment for COVID-19. The studys authors utilized electronic records to analyze the link between the two, concluding that melatonin usage was associated with a nearly 30 percent reduced likelihood of testing positive for SARS-CoV-2 after adjusting for age, race, smoking history and various disease comorbidities.

Marino describes the press release as irresponsible and factually unsupportable and says that while it is an interesting finding, its one that may be giving people false hope.

Melatonin is defined by the National Institutes of Health as a hormone that your brain produces in response to darkness. Classified as a dietary supplement by the Food & Drug Administration, it is one of the most widely used sleep aids in the U.S. While it is not regulated like a drug, many doctors have come to embrace melatonin, with the Mayo Clinic describing it as safe for short-term use, saying there is evidence showing that it provides some insomnia relief.

When used under doctors supervision, the supplement can be useful for alleviating sleep issues. But as a treatment for COVID-19, Marino says, its not a good idea. He elaborates on what he calls major problems within the study. One, the finding is an association only and, given the lack of any plausible mechanism, should not be mistaken for true cause and effect, says Marino. While I would not dismiss it outright, it would certainly be much easier to explain this through unidentified confounding factors for example, people who take melatonin are more likely to practice other interventions to try to protect their health.

Story continues

There are many reasons those taking melatonin may be experiencing COVID-19 in lower numbers, including improved sleep, better overall health and a more significant commitment to safety precautions.

On top of that, he suggests that only a randomized trial would be able to establish a causal connection. Observational studies like this are usually not able to show us whether anything truly prevents or treats a condition but just can identify correlations that then can be further studied, says Marino. The studys lead author, Feixiong Cheng, assistant staff in the Genomic Medicine Institute, seems to agree. In the press release on Cleveland Clinics site, Cheng advised against running out to buy the supplement.

It is very important to note these findings do not suggest people should start to take melatonin without consulting their physician, said Cheng. Large-scale observational studies and randomized controlled trials are critical to validate the clinical benefit of melatonin for patients with COVID-19, but we are excited about the associations put forth in this study and the opportunity to further explore them.

The Cleveland Clinic, in response to a request for comment, noted that the study was peer-reviewed and that the headline of the press release reflects the papers findings, adding the summary on Lerners web site emphasizes that this is a potential drug candidate for COVID-19 and further research is needed to validate theses initial findings.

After Marino tweeted about the study, other doctors expressed similar fears about the way it has been framed. It is simultaneously not at all surprising and incredibly disappointing that @ClevelandClinic is peddling bulls*** like this, and in so doing further eroding societal scientific literacy by spurring on predatory, clinical-evidence-not-required bandwagon fueling supplement sales, tweeted Dr. Yoni Freedhoff, an associate professor of family medicine at the University of Ottawa.

Like other experts, Marino emphasizes that the Centers for Disease Control and Preventions guidelines for staying safe remain the most important. As of right now there are no good treatment options for COVID-19, and the best way to prevent it is to practice distancing, masking and good hand hygiene, says Marino. A sure way to prevent disease spread is to avoid gathering in groups this Thanksgiving, as we are currently seeing uncontrolled virus spread in every part of the country.

For the latest coronavirus news and updates, follow along at https://news.yahoo.com/coronavirus. According to experts, people over 60 and those who are immunocompromised continue to be the most at risk. If you have questions, please reference the CDCs and WHOs resource guides.

Read this article:
No evidence that melatonin can be a treatment for COVID-19 - Yahoo Sports

Recommendation and review posted by Bethany Smith

Coronavirus research found a potential compound that can be found in foods.

Highlights

Health experts all over the world are in constant search for viable means to prevent and treat Coronavirus. Every day, we see a glimmer of hope in the numerous researches making headway in unravelling measures to combat the pandemic. One such recently-conducted research led by Cleveland Clinic found a new compound that is being seen as a promising drug against Coronavirus. Melatonin, a sleep-regulating hormone, was noted as the potential prevention and treatment of COVID-19. Humans naturally produce the hormone but in its absence, over-the-counter supplements and foods containing melatonin can be taken to overcome the deficiency.

The researchers analysed patient data from its COVID-19 registry and found that melatonin usage was associated with a nearly 30 percent reduced likelihood of testing positive for SARS-CoV-2 after adjusting for age, race, smoking history, and various disease comorbidities.

However, the researchers warned against starting taking melatonin supplements until further studies corroborate their findings that were published in the journal PLOS Biology. "It is very important to note these findings do not suggest people should start to take melatonin without consulting their physician," said Feixiong Cheng, PhD, assistant staff in the Genomic Medicine Institute and lead author on the study.

While we wait for validation on melatonin to reduce the risk of Coronavirus, you may consider consuming foods that are a natural source of melatonin. National Center for Biotechnology Information listed down the following foods that contain a good amount of melatonin.

(Also Read:Vitamin D Deficiency Found In 80% COVID-19 Patients; Diet Sources)

Melatonin is a sleep-regulating hormone.

Eggs are highly rich in proteins and can be consumed in abundance through breakfast diet. Boiled eggs, omelette, baked eggs, scrambled eggs, and more such egg-based recipes can be easily tried.

Another animal-based source of melatonin, fish is generally considered very healthy food to have, which provides many other nutrients as well.

3. Nuts

Out of all the plant-based sources, nuts have the highest amount of melatonin. Make it a habit to have a handful of different kinds of nuts every day.

This vegetable can be easily incorporated into our diet. Many Indian sabzis like mushroom matar and international dishes like mushroom pasta, can be made with mushrooms.

Try to consume different kinds of cereals to maximise nutrient-intake from this melatonin-rich food.

Promoted

Beans, lentils, chickpeas, peanuts - there's a whole range of legumes you can add to your regular diet. Thankfully, most of us already consume it in adequate quantities.

Note: These foods are not part of the study.

(This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.)

About Neha GroverLove for reading roused her writing instincts. Neha is guilty of having a deep-set fixation with anything caffeinated. When she is not pouring out her nest of thoughts onto the screen, you can see her reading while sipping on coffee.

The rest is here:
Experts Discover New Compound That May Fight Coronavirus; These Foods Are Natural Sources - NDTV Food

Recommendation and review posted by Bethany Smith

(HealthDay News) Patients with multiple primary melanomas have worse overall survival than those with a single primary melanoma, according to a study published online June 26 in JAMA Dermatology.

Abstract/Full Text (subscription or payment may be required)

Five-Year Survival Less Than 40 Percent in Seniors With DLBCL

FRIDAY, June 28, 2019 (HealthDay News) Overall survival among older adults with diffuse large B-cell lymphoma (DLBCL) has improved over time, but five-year survival is less than 40 percent, according to a study published online June 12 in Leukemia & Lymphoma.

Abstract/Full Text

Morning Preference Has Protective Effect on Breast Cancer Risk

FRIDAY, June 28, 2019 (HealthDay News) Morning preference seems to have a protective effect on breast cancer risk, according to a study published online June 26 in The BMJ.

Abstract/Full Text

Editorial

Use of 3-D Mammography Rapidly Expanded 2015 to 2017

FRIDAY, June 28, 2019 (HealthDay News) Adoption of 3-D mammography expanded rapidly in the United States in just a few years, particularly in areas with greater socioeconomic resources, according to a research letter published online June 24 in JAMA Internal Medicine.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Review: HPV Vaccination Program Has Considerable Impact

FRIDAY, June 28, 2019 (HealthDay News) The human papillomavirus (HPV) vaccination program has had a considerable impact, according to a study published online June 26 in The Lancet.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Infections Tied to Subsequent Risk for Acute Ischemic Stroke

FRIDAY, June 28, 2019 (HealthDay News) Different infection types, especially urinary tract infection (UTI), are associated with subsequent acute ischemic stroke, according to a study published online June 27 in Stroke.

Abstract/Full Text

USPSTF Lung Cancer Screening Too Conservative for Blacks

THURSDAY, June 27, 2019 (HealthDay News) Current U.S. Preventive Services Task Force (USPSTF) guidelines for lung cancer screening eligibility may be too conservative for African American smokers, according to a study published online June 27 in JAMA Oncology.

Abstract/Full Text (subscription or payment may be required)

Five-Year Overall Survival for Glioblastoma Persistently Low

THURSDAY, June 27, 2019 (HealthDay News) The percentage of patients achieving five-year survival following a glioblastoma diagnosis remains both steady and low, according to a study published online June 19 in Mayo Clinic Proceedings.

Abstract/Full Text (subscription or payment may be required)

MSSP ACOs May Not Improve Spending, Quality of Care

WEDNESDAY, June 26, 2019 (HealthDay News) After adjustment for the nonrandom exit of clinicians, the Medicare Shared Savings Program (MSSP) is not associated with improvements in spending or quality, according to a study published online June 18 in the Annals of Internal Medicine.

Abstract/Full Text (subscription or payment may be required)

Americans Concerned About Clinician Burnout

WEDNESDAY, June 26, 2019 (HealthDay News) Nearly three-quarters of Americans are concerned about burnout among their clinicians, according to a survey released June 17 by the American Society of Health-System Pharmacists (ASHP).

More Information

Combination Biopsy Strategy May Identify More Prostate Cancers

WEDNESDAY, June 26, 2019 (HealthDay News) A lesion visible on magnetic resonance imaging (MRI) identifies a heightened risk for clinically significant prostate cancer in men undergoing first-time prostate biopsy, and a combination of targeted and systematic biopsy may improve the chances of detecting cancer, according to a study published online June 12 in JAMA Surgery.

Abstract/Full Text (subscription or payment may be required)

Mortality Not Higher With Transfusions From Female Donors

TUESDAY, June 25, 2019 (HealthDay News) There is no increased risk for mortality among patients receiving red blood cell transfusions from female, previously pregnant, or sex-discordant donors, according to a study published in the June 11 issue of the Journal of the American Medical Association.

Abstract/Full Text (subscription or payment may be required)

Anesthesia Tied to Neurocognitive Impairment in Childhood ALL Survivors

TUESDAY, June 25, 2019 (HealthDay News) Multiple exposures to general anesthesia may be associated with neurocognitive impairment and brain imaging abnormalities in long-term survivors of childhood acute lymphoblastic leukemia (ALL), according to a study published online June 20 in JAMA Oncology.

Abstract/Full Text (subscription or payment may be required)

Voxelotor Improves Hemoglobin Levels in Sickle Cell Disease

TUESDAY, June 25, 2019 (HealthDay News) For individuals with sickle cell disease, 1,500 mg of voxelotor increases hemoglobin levels and reduces the incidence of worsening anemia compared with placebo, according to a study published in the June 14 issue of the New England Journal of Medicine.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Cancer Survivors Have High Prevalence of Chronic Pain

TUESDAY, June 25, 2019 (HealthDay News) Cancer survivors have a high prevalence of chronic pain, according to a research letter published online June 20 in JAMA Oncology.

Abstract/Full Text (subscription or payment may be required)

Nonchromosomal Birth Defects May Up Childhood Cancer Risk

MONDAY, June 24, 2019 (HealthDay News) Children with nonchromosomal birth defects have a higher relative risk for cancer, though the absolute risk is still low, according to a study published online June 20 in JAMA Oncology.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Adrenal Incidentalomas Rarely Grow, Change Hormone Function

MONDAY, June 24, 2019 (HealthDay News) Nonfunctioning adrenal tumors (NFATs) or adenomas causing mild autonomous cortisol excess (MACE) rarely show clinically relevant changes in size or hormone function, according to research published online June 25 in the Annals of Internal Medicine.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Drug Combo Slows Progression in Advanced Breast Cancer

MONDAY, June 24, 2019 (HealthDay News) Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, according to a phase 3 study recently published in the New England Journal of Medicine.

Abstract/Full Text (subscription or payment may be required)

Transfusion Dose Density Affects Myelodysplastic Syndrome Survival

MONDAY, June 24, 2019 (HealthDay News) Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study published online June 6 in Haematologica.

Abstract/Full Text (subscription or payment may be required)

Poor Oral Health Not Linked to Gastrointestinal Cancer Risk

FRIDAY, June 21, 2019 (HealthDay News) Self-reported poor oral health is not associated with gastrointestinal cancer risk, although it may be associated with hepatobiliary cancer, specifically hepatocellular carcinoma, according to a study published online June 8 in the United European Gastroenterology Journal.

Abstract/Full Text

Seniors Who Develop Cancer Have Better Memory, Slower Decline

FRIDAY, June 21, 2019 (HealthDay News) Older individuals who develop cancer have better memory and slower memory decline than those who remain cancer-free, according to a study published online June 21 in JAMA Network Open.

Abstract/Full Text

Editorial

Study Reveals Lower Predictive Ability for Renal Cancer Models

FRIDAY, June 21, 2019 (HealthDay News) Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology.

Abstract/Full Text (subscription or payment may be required)

No Change Seen in Processed Meat Consumption by U.S. Adults

FRIDAY, June 21, 2019 (HealthDay News) During the last 18 years, there has been no change in consumption of processed meats among U.S. adults, according to a study published online June 21 in the Journal of the Academy of Nutrition and Dietetics.

Abstract/Full Text (subscription or payment may be required)

First States to Expand Medicaid Had Largest Bump in Cancer Screening

FRIDAY, June 21, 2019 (HealthDay News) The first states to expand Medicaid under the Affordable Care Act saw the largest increases in colorectal cancer (CRC) screening from 2012 to 2016, according to a study published in the July issue of the American Journal of Preventive Medicine.

Abstract/Full Text

Restricting Blood Transfusions OK in Cardiac Surgery

THURSDAY, June 20, 2019 (HealthDay News) For high-risk patients undergoing cardiac surgery with cardiopulmonary bypass, a restrictive approach to red blood cell transfusions leads to fewer transfusions than a liberal approach, with no increase in the risk for acute kidney injury (AKI), according to a study published online June 20 in the Journal of the American Society of Nephrology.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Most Women Unaware Alcohol Poses Breast Cancer Risk

THURSDAY, June 20, 2019 (HealthDay News) Women have poor awareness of alcohols role in breast cancer risk, according to a study published online June 17 in BMJ Open.

Abstract/Full Text

New England Journal of Medicine Picks New Editor-in-Chief

THURSDAY, June 20, 2019 (HealthDay News) The new editor-in-chief of the prestigious New England Journal of Medicine is Eric J. Rubin, M.D., Ph.D., who was selected after a worldwide search and plans to start in September, according to the Massachusetts Medical Society, which publishes the journal.

More Information

Health Care Workers With ARIs Often Work While Symptomatic

THURSDAY, June 20, 2019 (HealthDay News) Almost all health care workers (HCWs) with acute respiratory illness (ARI) report working at least one day while symptomatic, according to a study published online June 18 in Infection Control & Hospital Epidemiology.

Abstract/Full Text

High Response Seen for Chemo in Seniors With High-Risk AML

THURSDAY, June 20, 2019 (HealthDay News) A substantial proportion of older patients with high-risk acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in Cancer Medicine.

Abstract/Full Text

Computer-Assisted Diagnosis Aids Detection of Glioma Growth

THURSDAY, June 20, 2019 (HealthDay News) Computer-assisted diagnosis (CAD) can help physicians detect growth of low-grade gliomas, according to a study published online May 28 in PLOS Medicine.

Abstract/Full Text

San Francisco Considering Banning Sales of E-Cigarettes

WEDNESDAY, June 19, 2019 (HealthDay News) A ban on the sale and distribution of electronic cigarettes is being considered by San Francisco supervisors. If passed, it would be the first such ban by any city in the United States.

AP News Article

Read the rest here:
Gout Linked to Increased Length of Hospital Stay in Patients With Heart Failure Exacerbation - Renal and Urology News

Recommendation and review posted by Bethany Smith

Transparency Market Research (TMR) () has published a new report titled,Endocrine Testing Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the globalendocrine testing marketwas valued atUS$ 5.5Bnin2018and is projected to expand at a CAGR of6.4%from2019to2027.

Overview

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1645

Rise in Prevalence of Endocrine and Metabolic Disorders to Drive Global Endocrine Testing Market

Thyroid Stimulating Hormone (TSH) Test Segment to Dominate Endocrine Testing Market

Request for Analysis of COVID19 Impact on Endocrine Testing Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1645

Clinical Chemistry Technology segment to dominate the Endocrine Testing Market

Commercial Laboratories Segment to be the Fastest Growing in theEndocrine Testing Market

Buy Endocrine Testing Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=1645&ltype=S

North America to Dominate Global Endocrine Testing Market

Competitive Landscape

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See the rest here:
Endocrine Testing Market projected to expand at a CAGR of 6.4% from 2019 to 2027 - Eurowire

Recommendation and review posted by Bethany Smith

Cardiovascular (CV) mortality is now the most common cause of death in men with prostate cancer, even exceeding prostate cancer mortality.1Several studies have shown androgen deprivation therapy, which is still the cornerstone of treatment for men with hormone-dependent prostate cancer, is associated with an increased risk of cardiovascular disease (CVD).2,3However, recent evidence suggests it is now time to consider which androgen deprivation therapy (ADT) modality is most suitable for patients with cardiovascular risk factors.4

The aim of this study was to use real-world data from a UK primary care database (Optimum patient care database) to clarify whether CV risk in prostate cancer patients was lower in those treated with GnRH antagonists vs. LHRH agonists. A total of 9,081 patients were identified from the database as patents with a diagnosis for prostate cancer and new users of degarelix, leuprorelin, triptorelin, or goserelin. We found patients receiving degarelix had a higher baseline prostate-specific antigen (PSA), indicating more advanced prostate cancer than those initiating therapy with a GnRH agonist. Further, more patients receiving degarelix had pre-existing CVD compared with patients receiving GnRH agonists. Despite this, the relative risk of experiencing any cardiac event was lower with degarelix than all GnRH agonists (Table 1; risk ratio [RR] 6.9% vs. 17.7%; 0.39 [95% confidence interval [CI] 0.191, 0.799]; p = 0.01).

Our data support findings from previously published studies showing GnRH antagonists are associated with a lower cardiac risk than LHRH agonists. In a retrospective pooled analysis of six prospective clinical trials in men with pre-existing CVD (2328), initiating degarelix compared with GnRH agonist therapy resulted in an absolute risk reduction of 8.2% (NNT=12).5Further, in a prospective randomized controlled trial of 80 patients with pre-existing CV disease, 20% on the agonist developed a major adverse cardiovascular event (MACE) compared to 3% on the antagonist.6Recent publications of similar real-world studies also reflect our findings. An analysis of Italian health records showed the incidence rate of CV events was significantly higher in patients treated with GnRH agonists rather than degarelix (8.80 vs. 6.24 per 100 person-year, p-value 0.002).7Further, pharmacovigilance data (VigiBase) showed increased odds of cardiac events (driven by myocardial infarction [MI] and heart failure [HF]), for GnRH agonists but not for GnRH antagonists.8Finally, a Phase III randomized controlled trial of an oral antagonist (relugolix) showed in pre-specified safety analysis, the incidence of major adverse cardiovascular events (MACE) was lower in the relugolix group than in the leuprolide group (2.9% vs. 6.2%, respectively).9

Our study, along with this recently published data highlights the importance of raising awareness of the CV risks for prostate cancer patients. A careful CV assessment should be considered in all patients undergoing hormonal therapy to identify those patients at high, intermediate, and low risk (Figure 1) and the optimal ADT identified to reduce the risk of future CV events. Further, is there a possibility that patients on long-term ADT initially considered intermediate risk may progress to high risk? This may be particularly important in patients with metastatic prostate cancer on a combination of ADT plus novel hormonal therapies such as enzalutamide and abiraterone, which have also been associated with increased cardiovascular mortality.10Those at high risk should receive appropriate lifestyle advice, regarding smoking cessation, healthy diet, weight control, and daily exercise and should be managed appropriately with European Association of Urology (EAU) guidelines recommending a cardiology consultation in men with a history of cardiovascular disease and men older than 65 prior to staring ADT1. American Urological Association (AUA) guidelines recommend patients on ADT are referred to their primary care physician for a periodic follow-up evaluation with appropriate secondary preventative measures in place for those patients with cardiac disease such as lipid-lowering therapy, antihypertensive therapy, glucose-lowering therapy, and antiplatelet therapy.11It is therefore important to consider personalized treatment for prostate cancer patients on hormonal therapies to optimize treatment options and reduce CV events.

Figure 1. Cardiovascular risk assessment

Table 1.Baseline characteristics and cardiovascular events in patients with prostate cancer treated with degarelix, leuprorelin, goserelin, or triptorelin

Written by: Patrick Davey, MD, PhD,Consultant Cardiologist, Northampton General Hospital, Northampton, UK;and Michael Kirby, MBBS, LRCP, MRCS, FRCP, Professor, University of Hertfordshire, Hatfield, England, United Kingdom

References:

Read more:
Cardiovascular Risk Profiles of GnRH Agonists and Antagonists: Real-World Analysis from UK General Practice - Beyond the Abstract - UroToday

Recommendation and review posted by Bethany Smith